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ABSTRACT 
 
There is a large medical need for the development of effective anticancer agents with 
minimal side effects. The present thesis represents an attempt to identify potent drugs 
for treatment of solid tumors. We used a strategy where 3-D multicellular tumor 
spheroids (cancer cells grown in three dimensional culture) were utilized as in vitro 
models for solid tumors. Drug libraries were screened using spheroids as targets and 
using apoptosis induction and loss of cell viability as endpoints. The hanging drop 
method for production of spheroids was modified to allow spheroid generation in the 
96-well format. Initial studies showed that the screening of multicellular spheroids 
resulted in the identification of different hit compounds compared to screening of 
monolayer cultures. Interestingly, we found that spheroid screening enriched for 
hydrophobic compounds (XlogP >4), a finding of considerable interest for chemical 
library design and lead optimization in the field of anticancer drug development. 
An approach based on the analysis of drug-induced gene profiles was used to 
unravel the mechanism of action of hits identified in the screen. The proposed 
mechanisms of action were subsequently confirmed by specific in vitro assays. 
The generation of a caspase-cleaved product of cytokeratin 18 was used to 
determine apoptosis of carcinoma cells in spheroids. The same method could be used as 
a plasma biomarker to evaluate whether candidate compounds induced apoptosis in 
xenograft tumor models. The antibodies used in the assay recognize human but not 
mouse cytokeratin 18 – an advantage when xenograft models are used since tumor 
apoptosis can be specifically measured in blood samples. 
 The screening work resulted in the identification of a novel topoisomerase 
inhibitor (thaspine), a novel iron chelator (CB21) and a number of microtubuli 
inhibitors.  
- Thaspine (an alkaloid from Croton lechleri) was identified in both monolayer and 
spheroid screening experiments. Thaspine was found to inhibit both topoisomerase I 
and II. Interestingly, thaspine was effective on cell lines overexpressing drug efflux 
transporters and showed in vivo activity. 
- CB21 was of particular interest, since it was toxic to the hypoxic quiescent cell 
population in spheroid cores which are known to be resistant to many 
chemotherapeutical drugs. The compound was not toxic to quiescent immortalized 
cells. CB21 was shown to be a very potent iron chelator. The compound induced 
marked induction of autophagy both in the outer and inner layers of spheroids. 
Interestingly, CB21 increased glucose uptake and reduced cellular oxygen 
consumption. The cytotoxicity of the compound was found to be increased during low 
glucose conditions, known to occur in the cores of spheroids. The compound showed a 
significant inhibitory effect in tumor xengrafts. 
- A number of novel microtubuli inhibitors were identified in the spheroid screen. This 
result was unexpected since such compounds are expected to be preferentially active on 
dividing cells.  
  
We conclude that drug screening using multicellular spheroids is a promising approach 
for anticancer drug discovery. A number of novel compounds were identified by 
screening, and some may be possible to develop for clinical use.  
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1 CANCER AS A DISEASE 
 
Cancer is a leading cause of death in humans, accounting for 13% of total death rates 
according to the WHO report 2008 (http://www.who.int/en/). It is still one of the most 
difficult diseases to treat. It represents a huge socioeconomic burden on nations 
considering billions of dollars spent per year on diagnosis, treatment, research, in 
addition to economic cost due to lost productivity of patients. 
 
Cancer is a disease in which a group of cells exhibit uncontrolled division leading to a 
primary tumor. A malignant tumor invades surrounding normal tissues causing their 
destruction. It may also spread into distal organs in the body through the lymphatic 
system or blood vessels.  Metastatic cancer leads to ~ 90% of all cancer-related deaths 
(Avendano and Menendez 2008).  
 
Many years of research has revealed that cancer results from the accumulation of 
mutations of genes in cancer cells giving them the advantages of unlimited division and 
evasion of apoptosis. These genes are either oncogenes with dominant gain of function, 
or tumor suppressor genes with recessive loss of function. Carcinogenesis is a multistep 
process in which healthy cells are gradually transformed into cancer cells (Hanahan and 
Weinberg 2000). Genomic alterations can occur due to internal factors like point 
mutations which can be induced by chemical carcinogens, translocation mutations or 
epigenetic changes, or due to external factors like viruses, chemical carcinogens or 
certain kinds of radiations, or due to hereditary factors like the involvement of BRCA1 
and BRCA2 hereditary mutations in breast cancer (Thurston 2007).  
 
In a highly cited article, Hanahan and Weinberg suggested six capabilities shared by 
most, if not all, human tumors: self-sufficiency in growth signals, insensitivity to 
growth-inhibitory signals, evasion of programmed cell death, limitless replicative 
potential, sustained angiogenesis and tissue invasion and metastasis. Cells must acquire 
all these traits to be malignant, explaining why carcinogenesis is multistage process 
occurring over many years (Hanahan and Weinberg 2000). 
 
A major problem associated with cancer is genetic instability. Recent sequencing 
studies of different cancer genomes revealed great mutational heterogeneity between 
different types of cancers (Greenman, Stephens et al. 2007). This heterogeneous nature 
occurs within cancers of the same organ origin and even within different cells of the 
same tumor. This phenomenon represents an enormous problem for cancer treatment. It 
is difficult to select a chemotherapy regimen which will be effective for a certain 
patient. Furthermore, the heterogeneity within different tumor cells in a tumor causes 
the emergence of clones that are resistant to specific chemotherapeutic agents, which 
ultimately leads to treatment failure.   
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1.1 MODALITIES FOR CANCER TREATMENT 
 
The major modalities for cancer treatment are surgery, radiotherapy, hormone therapy 
and chemotherapy.  Others modalities are less well established like immunotherapy and 
gene therapy. Surgery and radiotherapy are used in the removal of the primary tumor, 
however complete removal of all tumor cells are not guaranteed as residual microscopic 
cancer cells might still remain (as micro metastases at distal sites). Accordingly, 
subsequent chemotherapy is frequently needed to kill any residual cancer cells. 
Chemotherapy and radiotherapy can also be used preoperatively to shrink the tumor 
and facilitate its removal. Complete removal of tumor, however, by surgery can be 
limited if the tumor is anatomically adjacent to vital normal tissues (DeVita, Hellman et 
al. 2001). In addition, it is often that metastasis happens before diagnosis and treatment 
are started, accordingly the prognosis of the patient is not changed though the primary 
tumor is treated (Tobias, Hochhauser et al. 2010). This delineates the significance of 
chemotherapy as it has the advantage to access residual cells from the primary tumor or 
metastasized cancer cells by its systemic effect (Baquiran and Gallagher 2001).  
Chemotherapy is used to achieve cure, control or palliation in cancer patients, it can be 
the primary treatment or as an adjunct to other modalities like surgery or radiotherapy 
(Baquiran and Gallagher 2001). 
 
 
1.1.1 Chemotherapy 
 
The word “chemotherapy” was first coined by Paul Ehrlich, at the beginning of the 
twentieth century, in his attempts to treat syphilis using a chemical (Ehrlich 1913). The 
idea was not proven until Alexander Fleming discovered penicillin as toxic agent to 
bacteria (Fleming 2001). This discovery opened the era of research for chemical 
compounds to treat various diseases including cancer. However, not yet, that any 
anticancer agent approached such efficacy and specificity on cancer (Perry 2001). 
The ideal chemotherapeutic agent is the one which is cytotoxic or cytostatic to its target 
cells (i.e. the tumor cells), while being tolerated by normal body cells, in other words, 
an agent with wide therapeutic window. In case of antibacterial agents the mission is 
comparatively easier as bacteria possess targets that are unique from those of their host. 
On the contrary, cancer cells mostly share the same biochemical machinery of normal 
cells, accordingly, finding chemotherapeutic agents with selective toxicity to cancer 
cells is a major challenge (Perry 2001; Kamb, Wee et al. 2007) 
 
The first chemotherapeutic agent was discovered in the 1940s based on the observation 
that the soldiers in the world war II who were exposed to the warfare nitrogen mustard 
gas showed substantial myelosuppression and lymphoid hypoplasia (Lu and Mahato 
2009). This observation stimulated researchers to evaluate the therapeutic efficacy of 
this compound in treatment of hematologic neoplasms. A patient with advanced non-
Hodgkin’s lymphoma was treated with nitrogen mustard. Though the remission 
occurred by treatment was transient, the concept of using a chemical agent to treat 
cancers was established (Chabner and Roberts 2005). 
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1.1.2 Mechanistic classification of chemotherapeutic agents 
 
Anticancer agents can be classified according to their cellular targets. Examples of 
targets are DNA, RNA, enzymes necessary for cell proliferation, tubulin and the 
proteasome.  
 
 
1.1.2.1 Antimetabolites 
 
This group of agents blocks crucial metabolic pathways essential for cell growth. Like 
some other chemotherapeutic groups, they are toxic to dividing cells, explaining their 
well-known side effects on normal proliferating cells in bone marrow, GIT and hair 
follicles. This differential toxicity can be useful in case of some leukemia, but in case of 
older solid tumors, where they have small growth fraction, they have limited efficacy 
(Thurston 2007).   
 
Most of the antimetabolites interfere with DNA synthesis. For example, methotrexate 
works by inhibiting the activity of the dihydrofolate reductase enzyme which is 
responsible for conversion of dihydrofolic acid to tetrahydrofolic acid. The latter is 
required for synthesis of thymine which is a constituent of DNA. Other examples are 
the purine synthesis inhibitors 6-mercaptopurine (6-MP), tioguanine, fludarabine and 
cladribine or pyrimidine synthesis inhibitors like cytarabine (ARA-C) and 5-
fluorouracil (5-FU) (Huennekens, Bertino et al. 1963; Thurston 2007). 
 
 
1.1.2.2 DNA interactive agents 
 
The majority of anticancer agents exert their action through interaction with DNA. In 
general, proliferating cells are most sensitive to these agents due to difficulties of 
handling adducts or DNA breaks during DNA replication. Tumor cells frequently have 
damaged check-point systems and do not necessarily arrest their cell cycles to allow 
repair of damaged DNA. Progeny cells may be non-viable and die by apoptosis or other 
death modes (see further below). The mode of cell death following exposure to a DNA 
damaging agent is determined by many factors including cell type, the dose of the 
anticancer agent, type of DNA damage occurred and the genotype of the cell (e.g. p53 
mutation). Apoptosis could be the primary cell death mode like in some kinds of 
lymphomas. In such case, loss of apoptotic pathway for example by mutation of p53 or 
overexpression of Bcl-2 will affect the overall cell death. However, most cancers of 
epithelial origin do not die primarily through apoptosis. Thus, perturbation of apoptosis 
pathway will not affect the overall cell death. Nevertheless, apoptosis can occur 
secondarily to another cell death pathways like mitotic catastrophe, in what is called 
“funeral mode” (Brown and Attardi 2005).   
 
Interaction of these agents with DNA takes different forms. It can be through 
intercalation of the drug between the base pairs of DNA (e.g. doxorubicin and 
mitoxantrone) or alkylation of the DNA bases in the minor or major grooves (e.g. 
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dacarbazine and temozolomide). Other mechanisms are topoisomerase inhibition (e.g. 
irinotecan and etoposide), DNA strand cross-linking either by intrastrand or interstrand 
manner (e.g cisplatin and nitrogen mustards), or by DNA strand cleavage (e.g. 
bleomycins) (Thurston 2007; Avendano and Menendez 2008).  
 
As observed with other anticancer agents, the DNA interactive agents are toxic to the 
normal proliferating cells in bone marrow and GIT. This could be an explanation for 
the observed preferable toxicity towards the proliferating population of cancer cells. 
Another explanation could be the disrupted DNA mechanisms for DNA repair in 
cancer cells, compared to normal cells, and thus triggering cell death (Thurston 2007). 
In normal cells, the cell cycle checkpoints are used to ensure DNA repair for damaged 
DNA caused by usual factors like metabolic activities or external exposure to radiation 
or UV light (Harper and Elledge 2007). There are two checkpoints; G1 and S/G2 
checkpoints. In many cancers G1 checkpoint is defective where they rely on functioning 
S/G2 checkpoints for DNA repair. Checkpoint kinase 1 (Chk1), which is a major 
regulator for the S/G2 checkpoints, currently represents an attractive target to synergize 
the effect of DNA damaging agents. Inhibition of S/G2 checkpoints is believed to cause 
mitotic catastrophe and eventually cell death in G1 checkpoint defective cancer cells 
(Xu, Cheung et al. 2010).    
 
Cisplatin is an important agent in this group. Cisplatin was discovered by serendipity 
rather than systematic research (Rosenberg, Vancamp et al. 1965). Rosenberg and co-
workers observed a cytostatic effect on Escherichia coli on passing an electric current 
through platinum electrode. The effect was eventually attributed to platinum complexes 
formed electrolytically. Ciplatin acts by intrastrand cross-linking of the major groove of 
DNA. The bis-chloro molecule of cisplatin is stable and neutral in the chloride-rich 
plasmatic environment which becomes activated in the low-chloride intracellular 
milieu. The chloride ligands are being replaced by water molecules forming a 
positively charged aquated form which is highly reactive with nucleophiles (Ries and 
Klastersky 1986).  
 
Cisplatin is considered as a model for successful anticancer agents due to its 
pronounced activity particularly in testicular and ovarian cancers (Gottlieb and 
Drewinko 1975; Thurston 2007). Many papers of cisplatin-induced effects on tumor 
cells have been designed to examine short-term apoptosis. This generally occurs over 
24 hours and requires high concentrations of the drug. It has been shown in vitro that at 
high concentration, cisplatin induced apoptosis in enucleated cells, indicating that 
cisplatin-induced apoptosis can occur independently of nuclear DNA damage (Mandic, 
Hansson et al. 2003; Berndtsson, Hagg et al. 2007). The importance of short-term 
apoptosis is therefore unclear. 
 
Topoisomerase inhibitors are another class of DNA interactive agents. DNA 
topoisomerases I & II are nuclear enzymes which are responsible for the structure and 
topology of DNA. They play a major role in DNA replication and transcription by 
controlling unwinding and winding of supercoiled DNA (Sinha 1995). If unwinding of 
DNA fails, this causes failure of replication and transcription leading to cell death. 
Topoisomerase I induces single strand nicks while topoisomerase II is capable of 
inducing both single and double strand breaks (Sinha 1995), and after relieving the 
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DNA supercoiled tension by rotation, they reseal the DNA strands (Wang 2002). 
Topoisomerase inhibitors can act through direct inhibition of the enzyme or through 
intercalation with DNA. Examples of topoisomerase I inhibitors used in clinic are 
topotecan and irinotecan and for topoisomerase II inhibitors: etoposide, teniposide and 
amsacrine (Malonne and Atassi 1997)  
 
 
1.1.2.3 Antitubulin agents 
      
 Antitubulin agents interfere with microtubule dynamics of spindle formation and 
disassembly. Tubulin is the building unit of microtubules which are the the  integral 
components of the mitotic spindle. Microtubules are in dynamic equilibrium  between 
polymerization and depolymerization. Antitubulin agents work either by inhibition of 
tubulin polymerization or by stabilization of assembled microtubules and in both cases 
lead to inhibition of mitosis and subsequent cell death  (Pellegrini and Budman 
2005)(Thurston 2007). As antitubulin agents interfere with mitosis, it is generally 
believed that they exhibit toxicity only on proliferating cells. However, antitubulin 
agents also disrupts the cellular cytoskeleton, which a has a major role in intracellular 
transport and signal transduction, thus it would not be surprising that they can exert 
toxicity to the non-proliferating cells (Gundersen and Cook 1999; Giannakakou, 
Sackett et al. 2000). 
 
The major two families in this class of compounds are vinca alkaloids and taxanes. 
Both are of natural products origin. Vincristine and vinblastine belong to the vinca 
alkaloids which bind to tubulin and prevent its assembly into microtubules and thus 
inhibiting mitosis (Himes 1991). They have application in treatment of many kinds of 
cancer mainly breast cancer and certain kinds of leukemia and testicular carcinoma 
(Nelson 1982). Taxanes have a different mechanism of action compared to the vinca 
alkaloids. They stabilize the microtubule complex and inhibit its depolymerization, thus 
preventing mitosis. Paclitaxel is used in treatment of breast cancer, ovarian cancer and 
non-small-cell lung cancer. Docetaxel is a semi-synthetic taxane that was approved in 
1996 for the treatment of anthracycline-refractory metastatic breast cancer and later for 
treating platinum-refractory stage IIIB or IV non-small-cell lung cancer (Crown and 
O'Leary 2000; Montero, Fossella et al. 2005). Currently it is being used in the clinic for 
treatment of locally advanced or metastatic breast or non-small-cell lung cancer and 
androgen-independent metastatic prostate cancer (Engels, Sparreboom et al. 2005).  
 
The major side effect of microtubule inhibitors is neuropathy which can vary in onset, 
severity, reversibility depending on the agent used and its dose. Although the exact 
mechanism of neurotoxicity caused by antitubulin agents is not fully understood, 
preclinical physiologic and histopathologic studies indicate that it is principally a 
consequence of the interruption of axonal transport (Swain and Arezzo 2008). 
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1.1.2.4 Antihormonal therapy 
 
Hormones play a significant role in certain kinds of cancers like breast, testicular and 
endometrial carcinomas. Cancers arising from hormone- dependent tissues are 
themselves dependent on the same hormones for growth. This is evidenced by the 
observation of remission of breast cancer after ovariectomy in premenopausal patients. 
The same was observed in prostatic cancers after orchidectomy (surgical removal of 
testes) (Horsley 1947). Accordingly, antihormonal therapy is beneficial in such kinds of 
cancers. Though, not curative, they provide extended survival in selected patients 
sometimes for many years. Anti-estrogens (e.g. tamoxifen) and aromatase inhibitors 
(aminoglutethimide) are examples of antihormonal agents used in treatment of estrogen 
positive breast cancers (Hughes and Burley 1970; Jordan and Tormey 1988). 
 
 
1.1.3 Modern molecularly targeted agents 
 
Recent genetic and molecular studies have unveiled cell signaling networks controlling 
cell activities important for cell survival and proliferation. It has been found that many 
of these networks are radically disrupted in cancer cells (Chabner and Roberts 2005).  
The identification of these targeted drugs is based on experimental inhibition of a 
certain target thought to be upregulated in cancer cells and that cancer cells is 
dependent on it for their survival and proliferation. This new trend raised the hope for 
identification of anticancer agents with selective toxicity to cancer cells and less side 
effects compared to the conventional chemotherapeutic agents. 
 
The first successful agent belonging to the group of molecularly targeted agents is 
imatinib. It is a kinase inhibitor for the BCR-ABL fusion protein which is involved in 
the pathogenesis of chronic myeloid leukemia (CML). In addition, Imatinib also has an 
inhibitory effect on the KIT tyrosine kinase and platelet derived growth factor receptor-
β (PDGFRβ) tyrosine kinase (Chabner and Roberts 2005). Imatinib successfully 
induced 97% remission in case of earlier chronic phase of CML compared with 49% in 
the later blast-crisis phase (Kamb, Wee et al. 2007). 
 
A second example is the kinase inhibitor trastuzumab (Herceptin™). This is an 
antibody which inhibits the human epidermal growth factor receptor 2 (HER2)/neu 
signaling pathway with beneficial effect in breast HER2/neu positive cancer 
(Mannocci, De Feo et al. 2010). A further example is erlotinib (Tarceva™) which is an 
epidermal growth factor receptor (EGFR) inhibitor currently used in treatment of 
patients with non-small-cell lung cancer (Shepherd, Rodrigues Pereira et al. 2005).  
 
Proteasome inhibition represents a novel strategy for treatment cancer. The ubiquitin-
proteasome pathway is the principal route by which cells degrade proteins including 
signaling proteins. Thus, proteasome inhibitors retard or arrest cancer progression by 
interfering with the degradation of the regulatory proteins of cell activities (Myung, 
Kim et al. 2001). Bortezomib (Velcade™) is an example of proteasome inhibitors 
which proved efficacy in treatment of myeloma (Paramore and Frantz 2003).  
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Antiangiogenic agents are of considerable interest nowadays as a general mechanism 
for treatment of solid tumors. For any tumor to grow above the size of 1-2 mm
3 
a 
process of angiogenic switch should occur where new vasculature are formed to supply 
the tumor with oxygen and nutrients and thus sustain tumor growth (Folkman, Long et 
al. 1963). Bevacizumab (Avastin™) is a humanized monoclonal anti body which 
targets vascular endothelial growth factor A (VEGF) which is a proangiogenic factor 
(Ferrara, Hillan et al. 2004). Bevacizumab is approved by FDA in treatment of 
metastatic colon carcinoma in combination with 5-FU.  
          
 
1.1.4 Cancer growth kinetics and chemotherapy  
 
Tumor growth kinetics and chemotherapy-induced cell death are correlated such that 
the rate of chemotherapy induced regression is positively related to the growth rate of 
unperturbed tumor (Perry 2001). In case of human solid tumors, the rate of tumor 
growth is not compensated with an adequate vascularization leading to the formation of 
gradients of oxygen and nutrients throughout the tumor (Thomlinson and Gray 1955). 
A parallel pattern in proliferation profile is created according to these gradients: 
proliferating cells proximal to blood supply, hypoxic quiescent cells adjacent to the 
proliferating compartment and anoxic dead cells approximately >150 µm away from 
the blood capillary (Perry 2001)(Tobias, Hochhauser et al. 2010).  The proliferating 
subpopulation is called the growth fraction, which accounts for the overall growth of 
the tumor.  
 
Solid tumors growth kinetics is best described by the Gompertzian model which is a 
sigmoid curve. The model states that the growth fraction of a tumor decreases 
exponentially such that the larger the tumor the lower the growth fraction and vice 
versa. Large tumor growth rate almost follows a plateau when it approaches a volume 
that can kill the patient (DeVita, Hellman et al. 2001; Perry 2001). 
 
According to the mitoxicity hypothesis, proliferating cells have higher 
chemosensitivity, that is, tumors with high growth fraction are more responsive to 
chemotherapy. Clinically, curable cancers are those with high proliferation rate like 
testicular carcinoma and childhood acute lymphoid leukemia. This hypothesis can 
explain the toxicity of chemotherapy to rapidly dividing normal tissues like bone 
marrow, gastrointestinal mucosa and hair follicles (Holland 2000). On the other hand, 
the non-proliferating  hypoxic subpopulation are significantly less sensitive to 
chemotherapy (Perry 2001). One reason for this insensitivity can be attributed to their 
quiescence. Another explanation could be that these cells are located relatively far from 
the blood capillaries. Systemically administered drugs will not reach this subpopulation 
at therapeutic concentrations (Jackson 1989).   
 
After a chemotherapeutic dose resulting in the death of proliferating cells, these 
quiescent cells, upon the exposure to oxygen and nutrients, nourish and enter the cell 
cycle and proliferate (Jackson 1989; Mellor, Ferguson et al. 2005). This regrowth 
phenomenon, in addition to drug resistance, hinders the regression of the tumor aimed 
by chemotherapy. 
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1.1.5 Challenges in chemotherapy 
 
Resistance to chemotherapy and undesirable toxicity to normal cells are the major 
obstacles to chemotherapy (DeVita, Hellman et al. 2001). Accessibility of the drug to 
various populations of tumor cells, especially in solid tumors, in effective 
concentrations represents another obstacle in chemotherapy. It is believed that 
resistance is the cause for more than 90% of therapeutic failure in patients treated with 
conventional chemotherapeutic agents (Neidle 2008). Drug resistance has been 
reported in most drug-responsive tumors and for most classes of chemotherapeutics. 
Resistance can be intrinsic or acquired after exposure to chemotherapy. The 
conventional resistance theory suggests that subsequent chemotherapy cycles lead to 
the selection of resistant subclones causing diminished responsiveness by time. Cancer 
cells develop resistance via different mechanisms such as reduction of intracellular 
drug concentration through drug efflux pumps (multidrug resistance-MDR), increased 
drug inactivation, overexpression or modification of the target, signaling with different 
pathways and enhanced DNA repair machinery in case of DNA damaging agents 
(Gottesman 2002; Thurston 2007; Neidle 2008). Another important mechanism of 
resistance, though not widely discussed, is multicellular drug resistance in solid tumors 
(Kerbel, Rak et al. 1994; Grantab, Sivananthan et al. 2006). This kind of resistance 
emerges from the established contact of cancer cells with their microenvironment and 
acquisition of the three dimensional conformation. Quiescent tumor cells contribute to 
such kind of resistance (Desoize and Jardillier 2000). Which kind of resistance that is 
responsible for clinically observed resistance is still controversial. 
 
Another obstacle to successful therapy is the severe toxicity of chemotherapy to normal 
tissues. Chemotherapeutic agents are characterized by modest therapeutic windows. 
Nevertheless, the life threatening nature of the disease overweighs the serious side 
effects of chemotherapy. The most harmed tissues are the rapidly dividing like bone 
marrow, gastrointestinal crypt epithelial cells, hair follicle and stem cells (Baquiran and 
Gallagher 2001). Bone marrow toxicity is serious since it leads to anemia, leukopenia 
and excessive bleeding (Lu and Mahato 2009). Some strategies have been developed to 
combat some side effects like administration of hematopoietic growth factors like 
erythropoietin and colony-stimulating factors (CSFs) for treatment of chemotherapy 
induced anemia and neutropenia, respectively (Perry 2001). Furthermore, scheduling 
high doses of chemotherapy with interspersed intervals for normal tissue recovery and 
the use of cold cap to prevent alopecia are additional ways for reducing undesired side 
effects (Christodoulou, Klouvas et al. 2002). Yet, the best solution is the discovery of 
more selective anticancer agents with wider therapeutic index. 
 
From a pharmacological point of view, it is not sufficient for an anticancer drug to 
selectively inhibit its target cultured cells in vitro. It is of crucial importance that the 
agent targets the majority, if not all, cancerous cells in vivo. Pharmacokinetic properties 
of a chemotherapeutic agent are major determinant of the antitumor effect in patients. 
Pharmacokinetics science is the study of the time course of drug absorption, 
distribution, metabolism and elimination (ADME).  
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Many anticancer agents are administered intravenously giving 100% bioavailability 
circumventing limited GIT absorption and first pass effect (Figg and McLeod 2004). In 
hematologic cancers, all cells are exposed to the cancer agent, however in solid tumors 
the situation is different as the drug should distribute in therapeutic concentration to the 
different tumor compartments, including those which are distal from blood supply. 
Many factors determine the distribution of drugs to tumors such as cardiac output, 
plasma protein binding, blood flow within tumor, pH of the tumor, presence of drug 
efflux pumps and physicochemical properties of the drug (Figg and McLeod 2004). 
The later determine the pharmacological and drug-like properties of a chemotherapeutic 
agent which have a significant role in successful treatment. For example, a drug must 
have a balance between aqueous and non-aqueous solubility for appropriate distribution 
between aqueous and non-aqueous pharmacokinetic compartments including tumors 
(Neidle 2008). Metabolism, in most cases, converts drugs into less pharmacologically 
active compounds with polar properties to facilitate their excretion. In some cases, the 
metabolite is more active than the parent compound as in the case of CPT-11 and its 
metabolite SN-38 (Kawato, Aonuma et al. 1991). Thus, metabolism and excretion 
generally decrease the pharmacological response but at the same time reduces toxicity 
to normal cells (Figg and McLeod 2004).  
 
 
1.1.6 Combination chemotherapy 
 
The main principle of combination therapy is to enhance the efficacy of the 
chemotherapy regimen to kill cancer cells and accordingly, improvement of clinical 
outcome and patient’s survival. The heterogeneous genomic nature of cancer cells 
results in the presence of resistant cells to a specific chemotherapeutic agent. This 
causes clonal selection for resistant cells following successive chemotherapy courses 
and consequently treatment failure. Combination of anticancer agents with different 
mechanism of actions proved to be an efficient strategy to overcome such emergence of 
clonal resistant cells (DeVita, Young et al. 1975; Lu and Mahato 2009).  
 
Chemotherapeutic agents can be classified according to their activity during the cell 
cycle as cell cycle active or non-cell cycle active. Antimetabolites like 5-fluorouracil, 
methotrexate and 6-mercaptopurine are S-phase specific. Antimitotic agents such as 
vincristine and vinblastine are G2/M phase specific. DNA damaging agents like 
cyclophosphamide and doxorubicin are non-phase specific. Corticosteroids like 
dexamethasone and prednisone are examples for non-cell cycle active agents (Lu and 
Mahato 2009). 
 
The main criteria for selecting a combination therapy can be summarized as follows: 
 
1- Have different cell cycle specificity. 
2- Have different mechanism of action. 
3- To be effective as single agent. 
4- Have different side effects. 
5- Have different mechanisms of resistance development. 
 
 16 
 
Collectively, the major goal of combining two or more chemotherapeutic agent is to 
achieve synergetic or additive cytotoxicity on tumor without increasing toxic side 
effects on normal tissues.  
 
 
1.2 CELLULAR OUTCOMES OF CHEMOTHERAPY TREATMENT 
 
It has been believed that the mechanism of cell death induced by chemotherapy is 
confined to solely to apoptosis. Accumulating evidences suggest that tumor response to 
chemotherapy includes other modes of cell death (Brown and Attardi 2005) There are 
four modes of cell death described that can be induced by chemotherapy; apoptosis, 
necrosis, mitotic catastrophe and autophagy (Brown and Attardi 2005). Senescence, a 
form of permanent growth arrest, is not a cell death mechanism but is considered of 
significant importance as a response of cancer cells to chemotherapy. These five kinds 
of cellular responses are classified based on biochemical and morphological features 
present in dying cells.  
 
 
1.2.1 Apoptosis 
 
Although the phenomenon of apoptosis was described Carl Vogt in 1842 (Peter, 
Heufelder et al. 1997), the term “apoptosis” was first coined by Kerr, Wyllie, and 
Currie in 1972 (Kerr, Wyllie et al. 1972). Apoptosis, programmed cell death, is a 
conserved mechanism which multicellular eukaryotic organisms rely on for tissue 
remodeling and maturation. It also maintains tissue homeostasis by mediating 
equilibrium between cellular proliferation and death (Ricci and Zong 2006). The main 
morphological characteristics of apoptosis are cell membrane blebbing, cell shrinkage, 
chromatin condensation and nucleosomal fragmentation. Cells undergoing apoptosis 
form apoptotic bodies which are consumed by macrophages or neighboring cells. 
Apoptosis is commonly believed to be the major mechanism by which 
chemotherapeutic agents initiate cell death. Apoptosis is recognized as an energy-
requiring process. There are two distinct pathways for apoptosis execution; the 
intrinsic, or mitochondrial mediated pathway and the extrinsic, or extracellular 
activated pathway. The intrinsic pathway is activated by intracellular stress such as 
DNA damage (Eastman 1990), elevated levels of reactive oxygen species (Simon, Haj-
Yehia et al. 2000), viral infections (Hardwick 2001) or activation of oncogenes (Liu, 
Chen et al. 1998). The extrinsic pathway is induced by an extracellular ligand which 
binds to a certain receptor on cell membrane. Tumor necrosis factor (TNF) ligands, like 
TNF-α, FasL and TNF receptor apoptosis-inducing ligand (TRAIL), which bind to 
TNF receptors are examples of stimuli of the extrinsic pathway (Gross, Yin et al. 
1999). Both pathways activate caspases which are proteolytic enzymes that dismantle 
cellular organelles and structure (Ricci and Zong 2006). 
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1.2.2 Necrosis 
 
Unlike apoptosis, necrosis is considered as a passive, random, and uncontrolled cell 
death due to traumatic cell destruction followed by release of intracellular components. 
Necrosis is characterized by induction of an inflammatory response. Cell membrane 
distortion, mitochondrial and cellular swelling, organelles degradation, increased 
vacuolation are among the main morphological features of necrosis. Necrosis can occur 
as a consequence of pathophysiological condition like ischemia, infection, cellular 
membrane physical insults, imbalance in intracellular pH and calcium levels, energy 
depletion, increased ROS or inflammation (Okada and Mak 2004; Ricci and Zong 
2006) . Necrosis has been suggested as a cell death mechanism in response to some 
DNA alkylating agents, in rapidly growing cells like tumor cells. Highly proliferating 
cells select the aerobic glycolysis for production of ATP, since other non-glucose-
derived substrates like amino acids and lipids are used for synthetic purposes. On DNA 
alkylation, the nuclear enzyme PARP becomes activated and degrades NAD into 
poly(ADP)-ribose polymers and nictotinic acid mononucleotide (NAM). This leads to 
the depletion of cytosolic NAD pool and consequently inhibition of glucose dependent 
ATP production. Shutting down ATP production, ultimately lead to necrosis (Zong and 
Thompson 2006).  
 
 
1.2.3 Autophagy 
 
Autophagy is an evolutionarily preserved mechanism that occurs in all eukaryotic cells 
from yeast to mammals. Along with the ubiquitin-proteasome system, constitutive 
basal autophagy plays an important role in degrading accumulated cellular proteins and 
unneeded/damaged organelles thus maintaining cellular homeostasis (Levine and 
Klionsky 2004). Autophagy can be also triggered as a response to starvation or stress 
where cellular protein and organelles are degraded and recycled for energy production 
and sustaining cellular metabolism (Marino and Lopez-Otin 2004). Although most 
evidence support that autophagy is a prosurvival mechanism, it has been suggested that 
excessive cellular consumption by autophagy can lead to cell death (Mathew, Karantza-
Wadsworth et al. 2007; Meschini, Condello et al. 2011).  
 
The morphological features elicited in autophagy include cell membrane blebbing, 
partial chromatin condensation with no DNA laddering, cytosolic vacuolization, and 
degradation of Golgi, polyribosomes and endoplasmic reticulum. Briefly, autophagy 
process is initiated as a flattened vesicle in the cytoplasm which grows up to a cup-
shaped isolation membrane called phagophore which surrounds the selected protein or 
organelle. Eventually, this membrane closes to a double membrane autophagosome. 
The autophagosome then fuses with the lysosome forming an autolysosome which 
degrades the sequestered substances (Fleming, Noda et al. 2011). The genes controlling 
autophagosome formation are called autophagy-related (Atg) genes. Beclin 1 is a 
prominent member in this group (Levine 2007). On the molecular level, the pathways 
which lead to autophagy involve at least the phosphatidylinositol 3-kinase (PI3K) and 
the mammalian target of rapamycin (mTOR) pathways (Okada and Mak 2004). 
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1.2.4 Mitotic catastrophe 
 
Mitotic catastrophe is regarded as a trigger for cell death rather than a mechanism for 
cell death (Brown and Attardi 2005). It is proposed that mitotic catastrophe occurs due 
to deficient cell-cycle checkpoints (DNA structure and spindle assembly checkpoints) 
and cellular damage. Failure of arresting in the cell cycle, due to non-functioning 
checkpoints, before or during mitosis leads to an attempt for aberrant chromosomal 
segregation which in turn leads to induction of apoptosis (Castedo, Perfettini et al. 
2004). For example, irradiated cells which undergo mitotic catastrophe, revealed by cell 
fusion, polyploidy and failure of mitosis, ultimately might die through secondary 
apoptosis (funeral mode) (Brown and Attardi 2005). Mitotic catastrophe can also be 
induced by DNA damaging agents and antitubulin agents (Lock and Stribinskiene 
1996; Morse, Gray et al. 2005). Mitotic catastrophe is determined morphologically by 
the appearance of multinucleated cells and giant cells with intracellular micronuclei 
(Vakifahmetoglu, Olsson et al. 2008).  
 
 
1.2.5 Senescence 
 
Senescence was first described in 1961by Hayflick and Moorhead (Hayflick and 
Moorhead 1961). Until then, the finding of retarded and stopped division of cultured 
cells was thought to be a culture artifact. Human fibroblasts showed finite number of 
replication when grown in culture (Hayflick and Moorhead 1961) ending up in a state 
of growth arrest referred to as replicative senescence (Stanulis-Praeger 1987). This 
phenomenon was found to be due to progressive shortening of the repetitive DNA 
sequences found in the end of chromosome, so called telomeres (Goldstein 1990; 
Harley, Futcher et al. 1990). 
 
Morphologically, senescent cells become flattened with increased granularity. On the 
biochemical level, senescent cells show increased levels of β-galactosidase enzyme 
activity. Senescence can also be induced as a result of cellular stress. Although no 
shortening for telomeres are observed, these cells show the phenotypical characteristics 
of senescent cells (Okada and Mak 2004). DNA damage is one example of stresses that 
can cause senescence for cells. DNA damage activates p53 which primarily arrests cell 
cycle through the induction of p21. p21 is a pleiotropic inhibitor for different cyclin-
dependent kinases (CDKs). The induction of p21 is transient and is followed by stable 
activation of p16 (another CDK inhibitor). It is believed that p16 maintains cell cycle 
arrest after p21 shutoff. However, in tumor cells, results showed that the p53 and p21 
inhibition reduces but does not abolish DNA damage induced senescence. These 
findings indicate the involvement of other genes in the induction of senescence in 
response to DNA damage (Chang, Swift et al. 2002). It has been shown that cisplatin 
causes premature senescence, through its DNA damaging effect on cancer cells 
(Berndtsson, Hagg et al. 2007). The premature senescence program activates tumor 
suppressor genes such as those encoding the p53, p16, p21 and retinoblastoma protein 
(RB). This indicates that senescence has an antitumorgenic role as it stops the 
proliferation of tumor cells. This was manifested in vivo where mutated mice which are 
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incapable for induction of senescence develop cancer at early stage (Sharpless, 
Bardeesy et al. 2001). On the other hand, the induction of premature senescence in 
murine mammary epithelial cells prevented tumorigenesis (Boulanger and Smith 2001)  
 
 
1.3 PRECLINICAL EVALUATION OF ANTICANCER AGENTS 
 
Two approaches: cell based assays or biochemical screens for specific targets 
 
Systematic cancer drug discovery is based on screening of chemical libraries, either 
natural products or synthetic compounds, for anticancer activity in vitro. Cell based 
assay is the conventional approach where compounds are tested on cancer cell lines 
grown as monolayers. Such kind of screens leads to the identification of cytotoxic 
agents towards cancer cells but they may also be toxic to normal cells i.e. narrow 
therapeutic index. In order to find compounds with wide therapeutic indices, the target 
based approach was developed, especially after the increasing knowledge about the 
signaling networks in cancer cells, aiming to identify compounds that inhibit 
specifically upregulated proteins in cancer cells. However, the target based approach 
has its own shortcomings, for example, no proof that the identified hit is specific to the 
target (Balis 2002). In addition, cancer cells can compensate the inhibited pathway, by 
activation of alternative pathways, as a one form of resistance. Accordingly, target 
based hits may not be predictive for its effect on the whole cell (Balis 2002). 
 
Most currently chemotherapeutic agents were identified in cell based cytotoxicity 
assays (Balis 2002) and it is thought that this type of screen will continue to play an 
important role in cancer drug discovery. However, it was found that monolayers 
screening is not necessarily predictive for activity in vivo (Chabner and Roberts 2005). 
As an attempt to model solid tumors in vitro, Sutherland et al. developed the 
multicellular spheroid model (Sutherland, McCredie et al. 1971). Spheroids were 
shown to be superior to monolayers in modeling solid tumors in terms of growth 
kinetics, gene expression, cellular heterogeneity, three dimensional structure, 
multicellular resistance and secretion of extracellular matrix. Thus, spheroids can be 
used as a model for primary screening or as a secondary screening after a primary 
monolayer screen, preceding the in vivo animal testing.   
 
 
1.3.1 Spheroids as a model for preclinical evaluation of anticancer 
agents 
 
Experimental models which closely mimic solid tumors will provide better estimation 
for anticancer activity. Most anticancer studies are performed on cancer cell lines 
grown as monolayers. Although monolayers retain cancer characteristics, such as 
unlimited division and tumorigenicity in animal models, they lack the 3-D 
conformation and heterogeneity in cellular kinetics found in solid tumors (Yuhas, 
Tarleton et al. 1979). When potential antitumor agents are tested on monolayer 
cultures, all cells are exposed to the compound, a condition which does not exist 
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clinically in a multilayered tumor. Penetrability of an anticancer agent is a major factor 
for its efficiency, a criterion which cannot be detected in a monolayer model. 
Moreover, solid tumors are composed of proliferating and quiescent hypoxic cells 
which are known to be resistant (Roberts, Williams et al. 2009), while all monolayer 
cells are exponentially growing. Thus, monolayers hits are not necessarily toxic to 
quiescent cancer cells.  
 
Spheroids provide a better model for simulating solid tumors. They are produced by 
growing cancer cell lines three dimensionally (Inch, McCredie et al. 1970; Hamilton 
1998). The spheroids are of intermediate complexity between clinically observed 
tumors and cancer cell lines grown as monolayers (Sutherland and Durand 1976; 
Sutherland, Bareham et al. 1980; Hirschhaeuser, Menne et al. 2010). Subpopulations 
resistant to radiation and cytotoxic agents and with altered cell cycle distribution have 
been shown in spheroids (Freyer and Sutherland 1980). Cancer cell lines are more 
resistant to antineoplastic agent when grown as multicellular compared to the 
corresponding monolayers (Nederman 1984; Olive, Banath et al. 1993). Moreover, 
there is a correlation between the sensitivity of spheroids and that of in vivo models 
(Kobayashi, Man et al. 1993). The spheroid model has been used in different 
applications in cancer research; radiotherapy (Qvarnstrom, Simonsson et al. 2009), 
immunotherapy (MacDonald and Sordat 1980), chemotherapy (Twentyman 1980), 
angiogenesis (Gimbrone, Leapman et al. 1972), resistance (Chen, Wang et al. 2009), 
invasion (Mareel, Kieler et al. 1981), metastasis (Landry, Freyer et al. 1981), growth 
fraction (Yuhas and Li 1978), gene expression (Chang and Hughes-Fulford 2009)and 
extracellular matrix studies (Hirschhaeuser, Menne et al. 2010).  
 
In solid tumors, the homeostatic regulation of angiogenesis breaks down as a result of 
more rapid proliferation of tumor cells than the cells that form blood capillaries, 
creating a population of cells distant >100 µm from blood vessels (Thomlinson and 
Gray 1955; Brown and Giaccia 1998). This results in a gradient of decreasing tumor 
cell proliferation with increasing distance from tumor blood vessels (Tannock 1968; 
Gardner, Li et al. 2001). Spheroids reflect this situation as they contain three main 
subpopulations which are found in solid tumors; proliferating cells, hypoxic quiescent 
cells and dead cells (Sutherland and Durand 1976). Outer layers are proliferating as 
they have sufficient nutrients and oxygen while deeper layers become quiescent due to 
hypoxia and malnutrition in addition to high levels of cellular waste products (Freyer 
and Sutherland 1980), while the deepest layers become apoptotic/necrotic because of 
lack of nutrients and oxygen (Sutherland, Bareham et al. 1980; Hirschhaeuser, Menne 
et al. 2010). 
 
The ultimate goal of cancer therapy is to eradicate all tumor cells, as residual cells can 
repopulate the tumor. Clinically administered chemotherapy is believed to be toxic to 
proliferating cells (Holland 2000)(Valeriote and van Putten 1975; Remvikos, Mosseri 
et al. 1993; Siu, Arooz et al. 1999) and during recovery periods between cycles of 
therapy quiescent cells, which are far from blood supply, shift from quiescence to 
proliferation once exposed to nutrients and oxygen causing tumor regrowth (Siemann 
1998). In spheroids, it was shown that these dormant cells are capable of proliferation 
once exposed to appropriate conditions for growth (Durand 1975). Thus, to achieve a 
successful cure for solid tumors, the anticancer agent should be capable of penetrating 
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into the tumor parenchyme and being toxic to the distal hypoxic cells in addition to the 
proximal proliferating cells. In another words, the rate of tumor killing should be higher 
than the rate of tumor regrowth until the eradication of all cancer cells during a 
specified chemotherapy course (Shah and Schwartz 2000) 
 
Much of the initial preclinical characterization of anticancer agents is performed using 
cancer cell lines in monolayer culture (Neidle 2008). Under these conditions cells are in 
an exponential growth, a situation which is distinct from that occurring in 3-D tumors 
in vivo. Agents that are toxic to dividing 2-D cancer cells are not necessarily 
penetrating 3-D tumor tissue or toxic to non-dividing cancer cells. This, in part, might 
be the reason for the failure of hits from monolayer screens when tested in vivo and also 
for the unsatisfactory cure rates of currently used chemotherapeutic agents. Testicular 
cancer is characterized by high growth rate due to a high grow fraction (high percent of 
dividing cells) (Holland 2000). This might explain the exceptional success of 
chemotherapy in treatment of testicular carcinoma in case of solid tumors with cure 
rates exceeding 80% (Nakamura and Miki 2010). 
 
Many clinically used anticancer agents showed poor activity on multicellular spheroids 
(Sutherland, Eddy et al. 1979; Liao, Hu et al. 2010; Yu, Chen et al. 2010). Examples of 
such agents are cisplatin, doxorubicin, 5-FU and vinblastine (Mellor, Ferguson et al. 
2005). This might be attributed to limited penetrability of these drugs (Tunggal, Cowan 
et al. 1999; Tannock, Lee et al. 2002) in addition to their selective toxicity to dividing 
cells (Mellor, Ferguson et al. 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (1). Schematic illustration for a cell based approach for anticancer drug discovery. Drug libraries are 
directly screened on spheroids or alternatively, first screened on cancer cell lines monolayers, followed by a 
secondary screen on spheroids. Hits are then tested on animal models and promising agents enter clinical trials. 
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2 AIMS OF THE THESIS 
 
The main aim of the thesis was to identify compounds for treatment of solid tumors and 
to define their mechanism of action. Practically, we intended to generate uniform 
spheroids in the 96-well format and to find a suitable assay to screen drug libraries for 
cytotoxic/proapoptotic activity. We aimed also to validate animal xenograft models for 
testing the activity of identified hits in vivo. We finally asked the question of whether 
screening for agents active against tumor masses would enrich for specific physico-
chemical or mechanistic characteristics. 
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3 RESULTS 
 
3.1 PAPER I 
 
The aim of the paper was to adapt the hanging drop method for production of spheroids 
into the 96 well plates thus allowing high-throughput screening. We used apoptosis 
induction as an endpoint for efficacy evaluation of screened compounds. Apoptosis was 
detected using the M30-Apoptosense® enzyme-linked immunosorbent assay method 
performed in 96 well plates. Spheroids were produced by adding 20 µl drops containing 
1000 cells in the rings in the inner side of the lids of the 96 well plate, inverted, and 
then shaken for 2 hours in humidified CO2  incubator at 37 °C and were left for three 
days. Drops were then centrifuged to poly-HEMA coated round bottom 96-plates with 
100 µl medium with 10% serum (serum was filtered through 0.2 µm to remove 
particles that can deform spheroids structure) per well, and incubated for further four 
days. After seven days of seeding the drops, the generated spheroids were 
approximately 500 µm which is desirable to mimic the in vivo conditions of tumor 
masses. Moreover, this period (seven days after seeding) was found to be optimal time 
for assay assessment with regards to signal-to-noise ratio. Six out of eight epithelial 
cancer cell lines succeeded to produce spheroids namely, HCT116, FaDu, RT4, J82, 
LNCap and DU145. ACHN and A498 did not form appropriate spheroids. HCT116 
was selected for further studies because of the availability of various clones of this cell 
line where apoptotic pathways are disrupted giving the opportunity for more 
comprehensive apoptosis studies. In order to quantify the suitability of the assay and 
the model for high-throughput screening, we calculated the Z’ factor for the M30-
Apoptosense® assay on HCT116 spheroids. A value of 0.52 was obtained after 24 
hours treatment with 0.5 µM staurosporine (27 wells) and solvent (57 wells) which 
means by definition that it is an excellent model for large scale assays.  
 
This method was later simplified to avoid the centrifugation step (paper III – VI). In the 
modified method, 200 µL of cell suspension with 10,000 cells were added to each well 
of poly-HEMA-coated 96-well plates, and the wells were overﬁlled by adding an 
additional 170 µL media to acquire a convex surface curvature. Plasticine spacers (3 
mm) were placed in the corners of each plate to prevent the lids from touching the 
media. The plates were then inverted to allow the cells to sediment to the liquid–air 
interface. Plates were returned to normal position after 24 hr incubation allowing 
formed aggregates to settle in the bottom of the wells, excess media and spacers were 
removed. Plates were then incubated for further 4 days to produce spheroids with ~500 
µm diameter. 
 
After optimization and validation of our model, we tested the NCI COMBO Set, from 
the Developmental Therapeutics Program of the US National Cancer Institute, for 
apoptosis induction in HCT116 spheroids. The plate contains 77 compounds, 23 of 
which are anticancer drugs approved by the Food and Drug Administration (FDA). 
Various degrees of induction of caspase cleavage of CK18 were observed by these 
agents after 24 hours of treatment. 10 compounds were selected for more detailed 
studies. 24 and 48 hours treatments of these compounds were comparatively tested on 
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HCT116 monolayers and spheroids for apoptosis induction, and parallel assessment of 
viability after 24 hours treatments by counting Trypan blue negative (viable) cells. In 
case of spheroids, the 10 compounds showed correlation between apoptosis induction 
and loss of viability, while in monolayers correlation was found in 8 compounds. 2 
compounds, tentrandrin and miconazole, showed low apoptosis and low viability, 
presumably, the death mode shifted from apoptosis to necrosis at such concentrations. 
Various degrees of induction of caspase cleavage of CK18 by these agents were 
observed. Piroxicam was not significantly apoptotic for either monolayers or spheroids. 
Other compounds were apoptotic for both monolayers and spheroids like tamoxifen 
and pimozide. Cisplatin, a standard DNA-damaging agent, induced relatively more 
apoptosis in monolayers than in spheroids. 
  
A detailed description for culture, treatment and analysis of multicellular spheroids 
has also been published by Friedrich et al. (Friedrich, Seidel et al. 2009). These 
authors listed human carcinoma cell lines that produce spheroids under identical 
culture conditions. Assay end points were spheroid integrity and cell survival 
measured by the acid phosphatase assay. 
 
 
3.2 PAPER II 
 
In this paper we showed that we can detect apoptosis in the sera of mice with certain 
human epithelial xenografts using the M30-Apoptosense® ELISA independently of 
host toxicity.  
 
The M30-Apoptosense® ELISA assay detects caspase cleaved cytokeratin 18 (CK18) 
in human epithelial cells. It uses two antibodies: M5 as capture antibody and M30 as 
the HRP-conjugated deecting antibody. M30 is a monoclonal antibody which 
recognizes a neo-epitope formed after internal caspase-cleavage of human CK18 at 
Asp396 (Leers, Kolgen et al. 1999). Competition experiments were performed using a 
recombinant human CK18284−396 polypeptide and peptides corresponding to the C-
terminal caspase-cleavage site from different species. It was observed that the human, 
macaca mulata and bovine peptides competed more effectively with the CK18284−396 
polypeptide than those of mouse, rat, dog and xenopus. We concluded that the M30 
antibody recognizes the human, chimpanzee, macaca mulata  and bovine caspase 
cleaved CK18, but not that of mouse, rat, dog or xenopus. We also observed that the 
M5 capture antibody does not detect mouse CK18. 
 
Different human epithelial cancer cells lines were grown as xenografts in mice and 
treated with different cytotoxic agents. M30-Apoptosense® ELISA assay was used to 
detect caspase cleaved CK18 in mice plasma. Three SCID mouse models have been 
successful: FaDu head neck carcinoma, NCI-H146 small cell lung carcinoma and HT29 
colon carcinoma. In addition, nude rat model with colon carcinoma SW620 has also 
been successful. 
 
Time course studies to examine the release of cleaved CK18 in treated animals were 
performed. Two models were used: SCID mice with FaDu tumours and nude rats with 
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SW620. SCID mice with FaDu were treated with 5mg/kg doxorubicin intravenously. 
Increases of CK18-Asp396 from pre-treatment levels were observed in plasma of 
treated mice at 48, 72, 96 hours after treatment. In case of SW620 model, rats were 
injected intravenously with 25 mg/kg of the anti-mitotic agent AZ1152 (an aurora 
kinase inhibitor) for four consecutive days. Increases of CK18-Asp396 were observed 
in rat plasma at 3–5 days after treatment. However, the amplitudes of the increases 
induced by AZ1152 were much smaller compared to those found using DNA damaging 
agents, but were statistically significant. 
 
Thereafter, a dose response study was done in the SCID mice FaDu model using 
doxorubicin at doses of 0, 0.1, 2.5 and 12.5 mg/kg and 48 hour time point. Significant 
increases in the CK18-Asp396 levels were observed at the 2.5 and 12.5 mg/kg doses.  
 
We conclude from the experiments done that the M30-Apoptosense® ELISA assay is a 
useful tool for quantitative detection of apoptotic response induced by cytotoxic agents 
in xenograft rodent models bearing human epithelial cancer cell lines. The method is 
able to detect apoptotic response independent from animal toxicity. The results showed 
that time course and dose response studies can be performed using M30-Apoptosense® 
ELISA.  The assay can be used in preclinical evaluation of anticancer agents.    
 
 
3.3 PAPER III 
 
In this paper we investigated the effect of the standard chemotherapeutic agent cisplatin 
on HCT116 spheroids. We modified the method for production of spheroids as 
described above (see paper I).  
 
First we attempted to have deeper insight on growth characteristics of the HCT116 
spheroids. We found that the S-phase fraction dropped from ~40% at day 0 to ~10% 5-
7 days after seeding. This indicates significant reduction in the growth fraction 
consistent with that observed in tumors in vivo. By Ki-67 staining, it was shown that 
only the outer layers of the spheroids were dividing. Cells in the central portion of the 
spheroids stained positive for p27Kip1, a cyclin-dependent kinase inhibitor associated 
with quiescence (Eblen, Fautsch et al. 1995). 
 
Five days old spheroids were treated with 40µM cisplatin. This is a very high 
concentration, at least one magnitude higher than what can be achieved in vivo 
(Berndtsson, Hagg et al. 2007), but commonly used in in vitro studies of the effects of 
cisplatin on tumor cells. We aimed to address whether – even at such a high 
concentration – cisplatin induces significant apoptosis of HCT116 cells in spheroids. 
Clonogenicity was determined for both cisplatin-treated and untreated spheroids at days 
0, 2, 4, 6 and 8 after treatment. Spheroids were trypsinized, counted and 2000 viable 
cells were plated in 6-well plates. Untreated controls showed ~12.5% to ~15% 
clonogenicity in the different time points, while treated spheroids showed 0% 
clonogenicity at day 0 and gradually increased to ~2.5% at day 8. We stained sectioned 
treated spheroids for active caspase-3 to check whether acute apoptosis has a role in 
such reduced clonogenicity. Results showed that apoptosis was confined to the outer 
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layers (0–30 µm) at detected time points (0, 24, 48, 72 and 96 hr) where an increase in 
percent of positive cells was observed (~1.1% after 24 hr to ~3.8% after 96 hr). 
Increased caspase-3 activation was not observed in these cell layers in untreated 
spheroids during the same time span. A similar pattern of peripheral positivity was 
observed on staining for p53, p21Cip1 and p27Kip1 in sectioned treated spheroids, 
while untreated spheroids were negative. 
 
Although cisplatin caused significant reduction in clonogenicity, it was noticed that it 
did not eradicate spheroids even in long term. We examined the spheroids after 8 days 
of treatment. Treated spheroids diameters were similar to those observed at the onset of 
treatment and equal to ~75% of that of untreated spheroids. On counting, treated 
spheroids contained ~2 × 10
4
 viable cells compared to ~10
5 
cells in untreated controls. 
Approximately 5 % of treated spheroids cells stained positive for the senescence 
marker β-galactosidase while, untreated controls were < 5% positive. We concluded 
that a major fraction of cells are rendered senescent when spheroids are treated with 40 
µM cisplatin. Senescence was also observed after six days on treating HCT116 
monolayers with 10 µM cisplatin, >70% of the surviving cells were positive to β-
galactosidase staining and growth arrested. Growth arrest was assessed by staining with 
the PKH2 dye prior cisplatin treatment. The PKH2 signal is diluted in dividing cells, 
but not diluted in growth arrested cells and was determined by flow cytometry. Double 
staining with propidium iodide was used to determine the % of dying cells. Treated 
growth arrested cells showed ~45% dead cells compared to ~15% in the respective 
untreated cells. These data show that treated growth-arrested cells have a decreased 
long-term viability. 
 
Next, we investigated cisplatin effect in two in vivo xenograft models; SCID mice with 
HCT116 and FaDu cell lines. A dose of 2.5 mg/kg was used, and thaspine (Fayad, 
Fryknas et al. 2009) was used as a positive control in a dose of 10 mg/kg. Two 
parameters were considered; measuring of caspase-cleaved cytokeratin 18 in mouse 
serum after 48 hr as a marker for apoptosis and tumor size measurement. In the 
HCT116 model, cisplatin did not induce significant increase in cleaved cytokeratin 18 
and showed weak growth retardation in tumors. In FaDu model, we got different 
results, where cisplatin caused significant increase in cleaved cytokeratin 18 levels and 
no effect on tumors growth. It is noteworthy to mention here that cisplatin did not 
induce apoptosis in FaDu spheroids at 48 hr, revealed by immunostaining for active 
caspase-3. Therefore, it seems that apoptosis induction in tumors after 48 hr does not 
reflect cisplatin response. 
 
We conclude from the study that acute apoptosis is not the major mechanism by which 
cisplatin response occurs. In the HCT116 spheroid model, apoptosis was limited to the 
outer layers (mainly at 72-96 hr) and a major fraction of the cells were senescent after 8 
days of treatment. These senescent cells showed high spontaneous death compared to 
the untreated proliferating cells.     
 
 
 
 
 
 27 
 
3.4 PAPER IV 
 
About two-thirds of all approved anticancer agents are natural products or structurally 
related to them (Neidle 2008). We here screened a natural products library for apoptosis 
induction in a colon carcinoma cell line. The NCI natural products set (221 
compounds) was screened at 25µM on HCT116 cell line monolayers for proapoptotic 
activity after 24 hr treament. 20 hits were identified, 14 of which were with known 
targets. Thaspine (taspine; NSC76022) was selected for further investigation, as it had 
no known target and it is derived from the cortex of the tree Croton lechleri which is 
used in folk medicine.  
 
Thaspine induced apoptosis at 10 µM measured by M30 CytoDeath ELISA (a version 
of the M30 Apoptosense ELISA recently developed for in vitro use). Thaspine was 
found to induce the mitochondrial apoptotic pathway evidenced by the decrease in the 
mitochondrial membrane potential measured by flow cytometry of the fluorescent 
probe tetramethyl-rhodamine ethyl ester (TMRE). Bak and Bax are two key regulators 
in the mitochondrial apoptotic pathway (Hsu and Youle 1998; Griffiths, Dubrez et al. 
1999; Wei, Zong et al. 2001). Thaspine was here found to induce a conformational 
activation of Bak and Bax.  We furthermore found increased levels of cytochrome c in 
cytosol after thaspine treatment, as determined by Western blotting. In order to 
investigate which BH3 only protein has a role in apoptosis execution after thaspine 
treatment, an siRNA approach was used. Out of 9 tested siRNAs, Bid and Bik 
significantly reduced apoptsis, suggesting their role in thaspine-induced apoptosis.  
 
In order to elucidate the mechanism of action of thaspine, we used the Connectivity 
Map (CMAP) which is a method that compares the gene expression signature of a 
tested compound on certain cell line to a data base of gene expression patterns of drug-
treated cell lines (Lamb, Crawford et al. 2006). Thaspine was tested on MCF-7 cell line 
as the 1309 compounds in CMAP were tested on this cell line. Thaspine induced gene 
expression matched with ellipticine, a topoisomerase II inhibitor, and with 
camptothecin which is a topoisomerase I inhibitor. These data gave a hypothesis that 
thaspine is most likely a topoisomerase inhibitor. For proving this hyposthesis, we 
tested the inhibitory effect of thaspine on topoisomerase I&II in an in vitro assay. 
Indeed, thaspine inhibited both enzymes at a concentration of 10 µM. The assay in brief 
is based on measuring the inhibitory effect of tested compound on topoisomerase 
activity on a supercoiled plasmid. The topoisomerase enzyme converts the plasmid into 
its nicked form, while in case of inhibition of the enzyme, the supercoiled plasmid 
remains unchanged (as was noticed with thaspine). Different samples were detected by 
gel electrophoresis and staining with ethidium bromide. Furthermore, thaspine was 
found to to have a reduced cytotoxic effect on the viability on CEM/VM-1, a cell line 
selected for resistance to the topoisomerase II inhibitor teniposide compared to the 
parental cell line CCRF-CEM, adding more evidence that thaspine is a topoisomerase 
inhibitor. 
 
We then tested the efficacy of thaspine on some forms of resistance to chemotherapy. It 
was found that thaspine toxicity was marginally affected in two cell lines 
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overexpressing the membrane-associated drug efflux transporters P-glycoprotein (Pgp, 
ABCB1) and the multidrug resistance-associated protein (MRP, ABCC1).  
Interestingly, parallel testing using HCT116 spheroids showed that thaspine also 
induced apoptosis of 3-D cultured cells. We found that 20 µM of thaspine caused wide-
spread apoptosis in HCT116 spheroids after 16 hr treatment as revealed by staining 
with active caspase-3 in sectioned spheroids. This was paralleled by almost total loss of 
clonogenicity of thaspine treated spheroids (0.006% of untreated control). 24 hr 
treatment with 20 µM doxorubicin and 40 µM cisplatin caused limited induction of 
active caspase-3 in HCT116 spheroids. 
 
Next, we investigated the effect of thaspine in vivo. Three parameters were measured; 
immunostaining of HCT116 xenograft tumors sections for active caspase-3, caspase-
cleaved cytokeratin 18 in sera of mice bearing HCT116 and FaDu xenografts and tumor 
volume of FaDu xenograft. A single dose of 10 mg/kg thaspine was used in both tumor 
models. Treatment started when tumors were ~400 mm
3
. Positivity for active caspase-3 
was observed in treated HCT116 tumors sections after 48 hr treatment. At the same 
time point, a significant increase in cleaved cytokeratin-18 was observed in the sera of 
the treated mice both in HCT116 and FaDu xenografts. Apoptosis was paralleled by a 
significant, but transient, reduction of tumor size in the FaDu model. We conclude that 
thaspine is capable of induction of apoptosis in vivo. 
 
In summary, we identified thaspine as a novel dual topoisomerase inhibitor, from a 
screen of natural products. Thaspine induced apoptosis in HCT116 monolayers, 
spheroids and mice xenografts. It also induced apoptosis in FaDu xenografts with 
significant, but transient, tumor size reduction. 
 
 
3.5 PAPER V 
 
In this paper we used the multicellular spheroid model to screen for apoptotic/cytotoxic 
compounds. In addition to our previous characterization of HCT116 spheroids, we here 
showed that they contained a core of hypoxic cells as evidenced by staining for 
pimonidazole adducts. Killing this hypoxic subpopulation is essential for successful 
treatment. We aimed in this paper to identify compounds which are cytotoxic to both 
proliferating and hypoxic non-proliferating cells. Two distinct screens were performed, 
one where the library was screened both on HCT116 spheroids and monolayers and 
apoptosis was used as read-out and in a second where spheroids were screened for 
induction of apoptosis and loss of viability. In the second screen, the library was first 
screened on monolayer cells at a high drug concentration and continuous exposure to 
select active compounds.   
 
In the first screen, the NCI mechanistic set and the natural product set (999 compounds 
in total) were screened on HCT116 spheroids at 5 µM and 25 µM respectively. The two 
sets were in parallel screened on HCT116 monolayers at the same concentrations. 24 
hours exposure was used and apoptosis was the readout using the M30 CytoDeath 
ELISA. The 40 strongest hits were selected, and it was found that only 5 compounds 
were common in the identified spheroids and monolayers hits. We asked if the spheroid 
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hits enrich for certain chemical properties. We examined the molecular weight and 
XLogP of both sets of hits. It was found that the molecular weight did not differ 
significantly in monolayers and spheroids hits compared to libraries. On the other hand, 
it was found that spheroids hits selected against hydrophilicity, i.e. selects for 
compounds with higher XLogP values. The median XlogP of spheroids screening hits 
was 4.34 compared to a median XlogP of 3.16 in the libraries. The 10
th
 percentile of the 
XlogPs of 3-D hits was 1.27 compared to -0.55 of the libraries. In contrast, the 
distribution of XlogP values of 2-D active compounds did not differ significantly from 
the libraries. The strongest monolayer hit (NSC285116, siomycin A) was essentially 
inactive in 3-D culture. Siomycin A is a hydrophilic molecule (XLogP -3), likely to 
explain its poor penetration into spheroids. The hydrophobicity of 3-D active 
compounds was much higher compared to that observed in 18 standard 
chemotherapeutical drugs used as reference (median XlogP = 0.95). 
In the second screen, we screened the DIVERSet library form Chembridge (10,000 
compounds) on HCT116 monolayers at 25 µM with continuous exposure for 72 hours 
and assayed for general toxicity using the FMCA assay (Lindhagen, Nygren et al. 
2008). 382 hits were selected and rescreened on HCT116 spheroids at 25 µM with 6 
hours exposure followed by further 66 hours incubation in drug free medium. This 
time, both apoptosis and toxicity were used as readout. Apoptosis was detected by M30 
CytoDeath ELISA while toxicity was measured by the acid phosphatase assay as 
described by Friedrich et al. (Friedrich, Eder et al. 2007). The screen yielded 40 
compounds which were retested at different drug concentrations, and the 11 most 
potent compounds were selected for further studies. Again with regards to XLogP 
properties, similar to the first screen, these compounds showed a higher distribution of 
XlogP values compared to the library (median 4.40 versus 3.65) and there was a 
selection against compounds with low XlogP values (10th percentile = 2.70). We 
conclude that two independent screening procedures resulted in hits with very similar 
median XlogP values (4.34 and 4.40) and selected against hydrophilic compounds. 
 
Afterwards, we considered the 11 hits from the second screen for further mechanistic 
investigation. We started with cell cycle analysis, and it was found that seven of the 11 
compounds induced statistically significant increases in the number of cells in G2/M. 
Furthermore, visual inspection of the DNA flow cytometry profiles suggested that an 
eighth compound (5248881) also induced G2/M arrest, but that the profile was masked 
by dying cell debris. Three of 8 compounds that induced G2/M arrest (5268231, 
5346277 and 5350849) are sulphonamides, a class of compounds with reported 
microtubule inhibitory activity. This stimulated us to test the tubulin polymerization 
inhibition activity of these compounds in vitro. A number of the compounds showed 
some degree of inhibitory activity with 5248881 showing the strongest inhibition of 
polymerization with potency similar to colchicine. For adding more confirmation to the 
mechanism of action of these compounds, we used the CMAP technique (Lamb, 
Crawford et al. 2006) for comparison of the gene expression of our tested compounds 
to that of known compounds. Seven compounds showed a similar pattern to mitotic 
inhibitors including 5248881, 5276937 and 5350849. Then we attempted to investigate 
whether these compounds are selectively toxic to cancer spheroids and not toxic to 
normal non proliferating compounds. We set up spheroids from hTERT-RPE1, a 
normal human immortalized retinal epithelial cell line. Cell cycle analysis of RPE1 
spheroids showed that > 99% of the cells accumulated in the G1 phase indicating their 
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quiescence. 5 compounds with antimitotic transcriptional response were tested on both 
HCT116 and RPE1 spheroids. Spheroids were treated for 6 hours, washed, and then 
incubated for 5 days. Spheroids were trypsinized and tested for clonogenicity. Four of 5 
compounds reduced HCT116 spheroid cell clonogenicity of  > 70% while the 
clonogenicity of hTERT-RPE1 cells was reduced by 20% or less, indicating a 
promising therapeutic window.  Vinblastine, the known mitotic inhibitor showed 
selective toxicity towards cancer spheroids, while staurosporine and doxorubicin were 
100% toxic to the normal spheroids while showed 75% and 45% reduction in HCT116 
spheroids clonogenicity, respectively. 
 
The strongly tubulin depolymerizing compound 5248881 was studied in further detail. 
Staining spheroid sections for active caspase-3 showed that this compound induced 
apoptosis in the outer layers of the spheroids at 48 hours of treatment. The extent of 
caspase-3 activation by compound 5248881 was stronger than that observed using 
different standard tubulin inhibitors at tested concentrations. The volume of the area 
responding by apoptosis was estimated to be < 40% of total spheroid volume which 
could not account for the reduction of clonogenicity which was in the order of 80%. 
The antiproliferative effect of the compound on the cells of the spheroids can therefore 
not only be accounted for by induction of apoptosis. The possibility that the inner core 
cells are not clonogenic (contributing for the reduced clonogenicity) can be excluded in 
the light of NSC620358 results. NSC620358 is a compound identified in the screen and 
showed similar pattern of apoptosis induction (confined to outer layers) to that of 
5248881 compound. However, the clonogenicity of NSC620358 treated spheroids was 
only reduced by ~10%.   
 
We conclude from the work done that spheroid screening enriches for hydrophobic 
compounds. Mechanistic analysis revealed that the majority of the spheroid screening 
hits were microtubuli inhibitors. We identified the tubulin inhibitor 5248881 having a 
therapeutic window with selective toxicity to cancer spheroids and not to normal 
spheroids. The compound was found to be cytotoxic towards non-proliferating tumour 
cells in the spheroids but not to non-proliferating normal hTERT-RPE1 cells.   
 
 
3.6 PAPER VI 
 
In this paper, we identified CB21as a cytotoxic compound against HCT116 spheroids. 
CB21 was selected in the second screen outlined in paper V. As previously outlined, 
outer layers of the spheroids stained positive for Ki67 while inner layers were negative. 
Furthermore, the inner layers stained positive for p27 (cyclin dependent kinase 
inhibitor) and pimonidazole (hypoxia marker). We additionally show here that the core 
cells stain positive for the ER stress marker GRP78. All of these markers indicate that 
the inner spheroids cells are quiescent, hypoxic and stressed, all are characteristics of 
resistant cells in solid tumors.  
 
CB21 scored as cytotoxic to HCT116 spheroids both in apoptosis induction using the 
M30 assay and reduction of viability using the acid phosphatase assay. While, in non-
confluent untransformed hTERT-RPE1 epithelial cell line, the compound caused 
 31 
 
growth arrest but no cytotoxicity and for confluent cells it did not induce cell loss. 
Sectioned CB21 treated spheroids (6hr treatment followed by 96 hr incubation) were 
small and exhibiting a dead core.  
 
CMAP experiments suggested that CB21 is an iron chelator, as it induced similar gene 
experession as that of the known iron chelator ciclopirox olamine (CPX). Incubation of 
CB21 with iron chloride caused complete loss of activity, confirming that CB21 acts 
through iron chelation. Iron chelators are known to inhibit ribonucleotide reductase and 
thus inhibiting DNA synthesis (Nordlund and Reichard 2006). We found that CB21 
completely inhibited DNA synthesis at 24 hr treatment using BrdU incorporation assay. 
In addition, CB21 was equally toxic to HCT116 cells with wt p53 and disrupted p53. 
CB21 was the most potent in cytoxicity when compared to other known iron chelators; 
VLX50, deferasirox, ciclopirox olamine and deferoxamine (DFO). 
 
We observed formation of multible cytoplasmic vesicles in HCT116 cells treated with 
CB21. These cells stained positive with an antibody against LC3 protein indicating the 
induction of autophagy. Western blot confirmed this finding where both LC3-I and 
LC3-II were upregulated in CB21 treated HCT116 monolayers. LC3-II levels were also 
increased in CB21 treated HCT116 spheroids. In RPE1 cells, LC3-II was induced but 
to a lesser extent compared to HCT116 cells. This observation indicated that CB21 
toxicity is associated with autophagy. 
 
Different iron chelators induced LC3-I and LC3-II after 24 hr treatment on HCT116 
monolayers at toxic concentrations. This indicated that autophagy induction is a 
common mechanism caused by iron chelators. Electron microscopy for sectioned CB21 
spheroids showed autophagic vesicles both in outer layers and in deeper layers. We can 
conclude from this that CB21 is a penetrating compound which is able to induce 
autophagy in spheroids both in outer layers and deeper resistant cells. 
 
It is controversial whether autophagy is a rescue mechanism or a death mode (Kondo, 
Kanzawa et al. 2005). In order to answer the question if CB21 induced autophagy is a 
mechanism by which cells rescue themselves or dye with, we tested different 
autophagy inhibitors co-treated with CB21. We used 3MA, Bafilomycin A and siRNA 
against Beclin/Atg6. In all experiments, autophagy inhibition enhanced CB21 
cytotoxicity. We can conclude from this that autophagy is induced as a rescue 
mechanism as a result of certain metabolic insult caused by CB21.  
 
Results from CMAP showed that the hypoxia induced protein HIF-1α was upregulated 
by CB21. This was confirmed by Western blotting and by induction of GFP in a 
reporter cell line where GFP is regulated by HIF-1 α promotor. In addition, it is known 
that several proteins containing Fe complexes are involved in energy metabolism 
including oxygen consumption (Schieke, Phillips et al. 2006). This suggested the 
hypothesis that iron chelation affects oxygen consumption. We found two evidences of 
reduced oxygen consumptions. The first one by direct measurement of V3 (state 3) and 
Vu (uncoupled) respiration which were found to be significantly (p < 0.05) decreased 
after 6 hours of CB21 treatment. The second evidence was indirect using 
immunohistochemistry by staining for the hypoxia marker pimonidazole. CB21 treated 
sections showed ~50% decrease in hypoxic area. This means that cells’ consumption of 
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oxygen decreased on treatment with CB21 leading to abundance of oxygen and thus 
increase in the area of normoxic cells (Arteel, Thurman et al. 1998). As a control, 
HCT116 were treated with a mitochondrial uncoupling agent (carbonylcyanide-3- 
chlorophenylhydrazone, CCCP) known to increase oxygen consumption. CCCP treated 
sections showed larger area of hypoxia compared to untreated controls. 
 
BNIP3is a BH3-only protein which is regulated by HIF-1α (Bruick 2000). BNIP3 is 
reported to be involved in induction of autophagy (Vande Velde, Cizeau et al. 2000). 
Western blot showed that BNIP3 is upregulated by CB21, however silencing BNIP3 
did not inhibit LC3-II induction or cell death in HCT116 monolayers. BNIP3 was 
induced in RPE1 as well, indicating that BNIP3 is not responsible for cytotoxicity of 
CB21. 
 
mTOR is a serine/threonine kinase which regulates cell growth in response to nutrient 
status as well as mitochondrial oxygen consumption. We examined if CB21 reduced 
oxygen consumption is associated with mTOR inhibition. CB21 treatment caused the 
inhibition of the mTOR substrate 4E-BP1paralleled by increased Akt phosphorylation. 
The mTOR inhibitor rapamycin caused a reduction in the pimonidazole staining in 
sectioned spheroids though weaker than CB21. Although the dual PI3K/mTOR 
inhibitor NVP-BEZ235 was able to inhibit the phosphorylation of 4E-BP1 in spheroids, 
it did not exhibit cytoxicity on the inner layers of them. 
 
Decreased oxygen consumption is expected to increase the dependence on glucose for 
anaerobic energy production. We found that the hypoxic cells in the core of HCT116 
spheroids, but not the normoxic outer layers, died when grown in glucose deprived 
medium. Accordingly, the reduced oxygen consumption caused by CB21 is expected to 
increase the dependence of treated cells on glucose. This is what we found as the CB21 
treated cells showed higher death rate and apoptosis induction in glucose free medium 
compared to cells grown in usual glucose concentrations. 
 
Finally, we tested CB21 in mice xenografts. SCID mice with ~200 mm
2
 HCT116 
tumors were injected with a single i.v. dose (16 mg/kg) of CB21. The compound 
showed a significant growth inhibition in treated tumors until 15 days after treatment. 
These data are preliminary, studies are ongoing. 
 
In summary, we identified CB21 as a novel permeable iron chelator toxic to HCT116 
spheroids. The compound was non-toxic to untransformed human epithelail cells. 
CB21 induced autophagy associated cell death in the outer layers of the spheroids as 
well as the core cells known to be resistant to chemotherapeutic agents. The 
cytotoxicity of CB21 was enhaced by autophagy inhibitors. CB21 significantly 
inhibited tumor growth in a HCT116 xenograft model. 
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4 DISCUSSION 
 
 
4.1 MULTICELLULAR SPHEROIDS AS A MODEL FOR SOLID TUMOURS  
 
The main scope of the thesis was to identify compounds with curative potential to solid 
tumors. Alhough improvements in cancer treatment modalities have been achieved, 
current cure rates are not satisfactory for many forms of advanced cancer diseases  
(Kamb, Wee et al. 2007). Only a few forms of solid tumors can be treated with curative 
intent  when diagnosed at advanced stages, notably testicular carcinoma  (Carbone 
1990; Holland 2000). Accordingly, there is a large medical need for novel, efficient 
chemotherapeutic agents.  
 
We have chosen the multicellular spheroid model to screen for compounds which could 
potentially eradicate solid tumors. The model we chose was HCT116 colon carcinoma. 
Characterization of HCT116 spheroids revealed they are composed of outer 
proliferating layers and inner hypoxic quiescent cells. In immunohistochemistry 
staining, the outer layers stained positive for the proliferation marker Ki67 while the 
inner layers did not. In addition, the inner layers stained positive for p27, pimonidazole 
and GRP78 indicating their quiescence, hypoxia and ER stress, respectively. It has been 
shown that spheroids > 200 µm consume ~1/4 of oxygen compared to the exponentially 
growing spheroids of < 200 µm diameter (Freyer, Tustanoff et al. 1984). The hypoxic 
non-proliferating subpopulation is of particular interest as this cell population is known 
to be therapy resistant, and thought to be responsible for tumor regrowth. Finding 
compounds which are toxic to this subpopulation of cells provides a promising strategy 
for identification of effective drugs for treatment of solid tumors. Additionally, the 
three dimensional nature of the spheroids allows the identification of penetrating 
compounds, which is an essential characteristic for an agent effective on solid tumors. 
We have shown that apoptosis induction of a high dose of 40 µM cisplatin was limited 
to the outer layers of the spheroids, and did not eradicate the spheroids even after eight 
days of incubation, most probably because of its poor penetrability. 
 
 
 
 
 
 
 
 
 
 
Figure (2). Immunohistochemical characterization for HCT116 colon carcinoma spheroids. Outer layers are stain 
positive for the proliferation marker Ki-67, while the spheroids core is stained positive for the cyclin dependent 
kinase inhibitor p27, the hypoxia marker pimonidazole and ER stress marker GRP78. 
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This triggered us (in papers V & VI) to use the spheroid model for screening drug 
libraries aiming to find compounds able to penetrate the tumor mass and being toxic to 
the inner hypoxic quiescent spheroid cells as well as the outer proliferating cells.  
 
In our second screen (paper V and paper VI), we used a six hours exposure time, 
followed by washing and further incubation a step to mimic clinical situation where the 
compounds are washed away from the body through metabolism and excretion. This 
step also allows the identification of penetrating compounds, excluding the possibility 
that the activity of the drug is attributed to killing the spheroids layer by layer in case of 
continuous exposure. In this screen also we introduced a counter screening step where 
we used the normal human immortalized retinal epithelial RPE1 cell line, in an attempt 
for early identification of compounds with wide therapeutic window. 
  
 
4.1.1 Spheroids as a model for studying combination therapy 
 
Spheroids can be multiply treated owing to their three dimensional nature, making it 
possible to use them as a model for studying complex combination therapy modalities 
where drugs are used at separate times. It seems reasonable to assume that alternating 
treatment using cytotoxic agent and cytostatic agent can lead to decreases in tumor 
mass.  An illustration is shown in the figure below. HCT116 spheroids were treated 
with a cytotoxic agents (NSC620358, 20 µM) identified in our screen. NSC620358 is a 
proteasome inhibitor which shows strong cytotoxicity to the peripheral cell layers of 
HCT116 (actually “peeling” these cells off, leaving inner cell layers intact) (manuscript 
in preparation). Following treatment with the cytotoxic agent, there is a slow increase in 
the size of the spheroids (associated with an increase in Ki67 and cyclin A positive 
cells). Whether this combination of compounds will be effective in vivo, and whether 
the cytotoxic treatment can be repeated until the tumor mass is eradicate, is not clear. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (3). Effect on HCT116 spheroids of the combination of the cytotoxic agent NSC620358 (comp.10) (20 µM) 
and the PI3K/ mTOR inhibitor NVP-BEZ235 (0.2 µM). Spheroids were treated with NSC620358 for 24 hours on 
Day 4. After treatment, spheroids were incubated with or without NVP-BEZ235 as indicated. Diameters were 
measured in quadruplicate wells. 
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4.1.2 Methods for generating multicellular spheroids 
 
Different methods have been described for making spheroids. The common concept of 
these methods is to grow cancer cells in a non-adherent substratum like agar, agarose or 
Poly(2-hydroxyethyl methacrylate) (poly-HEMA) (Folkman and Moscona 1978). The 
main methods used for generation of spheroids are spinner flask method (Moscona 
1957; Moscona 1968), liquid overlay method (Rofstad, Wahl et al. 1986; Enmon, 
O'Connor et al. 2001; O'Connor and Venczel 2005), gel encapsulation (Kupchik, 
Langer et al. 1983; Kupchik, Collins et al. 1990; O'Keane, Kupchik et al. 1990; 
Hoffmann, Schirner et al. 1997) and hanging drop method (Kelm, Timmins et al. 2003; 
Del Duca, Werbowetski et al. 2004; Timmins and Nielsen 2007). With exception to the 
hanging drop method, the other methods have the drawback of production of spheroids 
of heterogeneous sizes. This makes it unsuitable for high throughput screening. One 
method for generation of spheroids in 96-well plates has been described based on the 
liquid overlay method combined with a centrifugation step (Ivascu and Kubbies 2006) 
but on trying it in our lab it did not produce single spheroid per well. The hanging drop 
method is characterized by generation of homogenous spheroids but the problem with it 
is the need for transferring procedure making it tedious for screening purpose.  
 
In the present study, we introduced two new methods for production of spheroids in the 
96-well plates. The two methods are based on combination of hanging drop principle 
and liquid overlay method. These methods produced single spheroid per well, with 
uniform sizes. For HCT116 colon carcinoma, we obtained a Z’ factor (Zhang, Chung et 
al. 1999) of ~0.5 for both methods using the M30-Apoptosense® assay indicating that 
these models are excellent for high throughput screening. One method, which is based 
on flipping the plate, succeeded to produce spheroids from the FaDu cell line and the 
immortalized human epithelial retinal RPE1 cell line. The introduction of a shaking 
step for the inverted plate significantly improved the ability of the cell lines to form 
spheroids and the homogeneity of generated spheroids.  
 
 
 
 
 
 
 
 
 
 
 
Figure (4). Two methods for generation of spheroids in 96-well plate were developed based on the hanging drop 
method. (A). 20 µl cell suspension drops were added to the inner side of the 96-well plate lids which were shaken, 
incubated, centrifuged to poly-HEMA coated 96-well plates, then incubated further till formation of spheroids with 
the required size. (B). 96-well plate wells were overfilled with cell suspension to obtain convex surface. The plates 
were then flipped, shaken (if required) and incubated for 1-2 days. Media is kept in wells by surface tension. Plates 
are then flipped back, allowing aggregates to settle down in the poly-HEMA coated bottom. Aggregates were 
incubated further until forming the desirable size spheroids.  
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4.2 THE M30 ASSAY FOR DETECTION OF APOPTOSIS 
 
Throughout the present study, we used the M30 Apoptosense® assay for detection of 
apoptosis induction in vitro and in vivo by different tested agents (Linder 2007). It is 
available in 96-well format. The assay detects caspase cleaved CK18 in epithelial cells. 
The advantage of this assay that it is applicable to cell cultures in vitro as monolayers 
(Hägg, Biven et al. 2002; Erdal, Berndtsson et al. 2005), spheroids (Herrmann, Fayad et 
al. 2008). In addition, the method can be used to determine tumor cell death using 
plasma/serum samples from human xenografts and patients (Ueno, Toi et al. 2003; 
Kramer, Erdal et al. 2004) .  
 
Available cytotoxicity assays for monolayer cultures are not necessarily suitable for 
performance on the spheroid model. Standard methods such as MTT and XTT assays 
rely on exogenous substrates, which may not diffuse into the depth of the spheroids. It 
is therefore possible that such assays only measure the viability of a subpopulation in 
the spheroids. The M30 ELISA assay overcomes this obstacle as it measures the 
endogenously produced caspase cleaved CK18. Both intracellular and extracellular 
cleaved CK18 are detected, by the aid of freezing and thawing the spheroids and by 
addition of non-ionic detergent. Another advantage of the assay that it is accumulative 
in nature, as it measures the accumulated produced cleaved CK18 which is stable in the 
culture medium. This is in contrast with other apoptosis assays, like caspase-3 
measurement, which require an optimum time point for detection of apoptosis. 
 
 In addition to the M30 assay, we used the acid phosphatase assay, for measurement of 
general toxicity (Friedrich, Eder et al. 2007). Similar to the M30 assay, this assay 
measures an endogenous substrate which is the acid phosphatase enzyme, explaining its 
suitability for the spheroids model. One problem we faced with acid phosphatase assay 
is the presence of background levels in spheroids where all cells were dead as 
determined by clonogenic assay. We believe that this background is from dead cells in 
the middle of the spheroids where acid phosphatase may be entrapped and could not be 
washed away during the washing steps. In many experiment we subtracted the 
background levels from all samples including the untreated controls. 
 
We here showed the applicability of the M30 assay in rodents’ xenografts (Paper II). 
The assay does not detect mouse/rat caspase cleaved CK18 – making the M30 
Apoptosense ELISA a useful tool for determining whether drugs induce apoptosis in 
human xenograft tumors in rodents. We considered two main possible sources for the 
elevated levels of cleaved CK18 in blood. Both possibilities are related to tumor cells 
which are adjacent to blood vessels. The first explanation is that apoptotic bodies, 
which are not engulfed by neighboring cells and macrophages due to overload, undergo 
secondary necrosis and disintegration. This is followed by the release of the contents of 
these bodies into circulation (Chang, di Tomaso et al. 2000). The second possibility is 
based on the fact that cancer cells which form part of the vessel wall (mosaic vessels) 
are shed into circulation. It is estimated that around one million cancer cells are shed 
into circulation per day for one gram tumor. These cells are known to have high 
apoptotic index (Larson, Moreno et al. 2004). Hou et al (2009) showed that plasma 
M30 concentrations correlated to the number of apoptotic circulating tumor cells (Hou, 
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Greystoke et al. 2009), consistent with this interpretation. We studied the effect of 
cisplatin in two mice xenograft models bearing HCT116 colon carcinoma and FaDu 
head and neck carcinoma cell lines (Paper III) (Xu, Cheung et al. 2010). Despite the 
very limited apoptosis detected in the spheroid model, we did detect some caspase-
cleaved CK18 in the plasma of treated mice. The induction of caspase-cleaved CK18 
by cisplatin was not, however, correlated with the tumor volume reduction. This 
observation is consistent with a model where the cancer cells which are close to the 
blood vessels are the source of the apoptotic signal while the bulk of the tumor is not 
affected by cisplatin causing undetectable decrease in tumor volume. This agrees with 
what we found in restriction of acute apoptosis induced by cisplatin to the outer layers 
of the HCT116 spheroids.  
 
This observation raises the question if apoptosis induction is a relevant screening target. 
Most of anticancer agents are thought to exert their efficacy through induction of 
apoptosis. Paradoxically, evasion of apoptosis is a hallmark for most if not all types of 
cancers. Recent studies support the involvement of other modes of cell death/arrest like 
necrosis, mitotic catastrophe, autophagy and senescence as a response to chemotherapy. 
We believe that apoptosis induction will remain an interesting mechanism for discovery 
of new and more effective antineoplastic agents. However exploration for compounds 
which induce other types will be beneficial in the light of the fact that apoptosis 
mechanisms are disrupted within cancer cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (5). Two hypotheses explaining elevated levels of M30 in blood of cancer patients. (A). Tumor cells first 
undergo apoptosis, rupture, and followed by releasing of M30 into circulation. (B). Tumor cells which that are part of 
the vessel walls of mosaic vessels are shed into blood where they undergo apoptosis.  
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4.3 CHEMICAL PROPERTIES OF SPHEROIDS SCREENING HITS 
 
In the present thesis we report the first relatively large scale screening of drug libraries 
for cytotoxicity/apoptosis induction on cancer spheroids. We validated the screening 
procedure by testing the COMBO plate (77 compounds) from the NCI then we 
performed two main screens. The first one was for the mechanistic set (827 
compounds) and the natural product set (221 compounds) both provided by the NCI, 
and the second screen for 382 hits from a monolayer screen of 10000 compounds from 
the DIVERSet library purchased from Chembridge company. The screens were 
performed on the colon carcinoma cell line HCT116. The total number of compounds 
screened on spheroids is 1458 taking in consideration the overlap of some compounds 
between the natural products and mechanistic sets. 
 
A total of 999 compounds from the mechanistic set and the natural products set were 
screened on both HCT116 monolayers and spheroids for apoptosis induction. 
Interestingly, the screens yielded different sets of hits. Only 5 compounds were 
common in the strongest 40 hits. This finding indicates that the selection of the 
experimental model affects significantly the path of the research and consequently the 
usefulness of the obtained results. 
 
 It has been reported that resistance to anticancer agents can be overcome by increasing 
their lipophilicity (Fry and Jackson 1986; Seiler 2005; Verma 2006). This could be 
attributed to the enhanced penetrability into the tumor parenchyme. In our first screen 
we studied the chemical properties of both sets of monolayers and spheroids hits, with 
regards to molecular weight and lipophilicity and addressed the question whether the 
spheroids model enriches for compounds with certain characteristics. The molecular 
weight distribution did not differ between monolayers hits and spheroids hits. However, 
the spheroids screen selected for hydrophobic compounds with high XlogP values. The 
same finding was observed in the second screen. These results suggest that hydro-
phobic compounds are more capable of penetrating the tumor mass than hydrophilic 
compounds. The median XlogP of 18 standard chemotherapeutic agents was 
significantly lower than that of the spheroids hits, a possible explanation for their 
limited efficacy on spheroids and solid tumors. The most potent monolayer hit was 
siomycin A, this compound was inactive on spheroids in the M30 assay and in caspase-
3 induction in the immunostained sectioned spheroids. Siomycin A is a hydrophobic 
compound with XlogP of -3, adding more evidence for the assumption that 
hydrophobicity is a major factor for the efficacy of anticancer agents on 3-D tumors. 
 
One point to be outlined here is that the hydrophobic hits are not soluble in aqueous 
solvents. This necessitates an additional effort for formulating such compounds for in 
vivo testing. We faced this problem with the iron chelator CB21 which precipitated in 
the mice when injected subcutaneously. Considerable work had to be performed to 
obtain a proper formulation where no precipitation of the compound occurred. 
 
To summarize, our findings have implications for drug design and lead compounds 
optimization. The findings suggest that screens aimed to identify compounds effetive 
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on solid tumors should use chemical libraries where the XlogPs of the compounds are 
in the order of 3 – 5.  
 
 
4.4 MECHANISTIC PROPERTIES OF SPHEROIDS SCREENING HITS 
 
In the current study, we identified 13 compounds cytotoxic to cancer spheroids. The 
mechanism of action of majority of the hits was inhibition of tubulin polymerization: 
seven compounds were microtubuli inhibitors, one was a dual topoisomerase inhibitor 
and one was an iron chelator.  
 
One possible explanation why we got many tubulin inhibitors as hits is that   tubulin 
polymerization is a sensitive process that is easily disrupted by chemical agents. These 
agents target tubulin, the evolutionary conserved building unit of microtubule (Buiret, 
Combe et al. 2010). Most of the clinically available microtubuli inhibitors like taxol, 
vinorelbine, colchicine, vincristine and vinblastine are natural products obtained from 
different species indicating that tubulin has been selected as target at different 
evolutionary occasions (Hamel 1996). As spheroids contain high fraction of non-
dividing cells, it was surprising to identify agents which are toxic to proliferating cells 
like the antimitotic microtubuli inhibitors. However, it has been reported that 
microtubuli inhibitors can be toxic to non-dividing cells (Leoni, Hamel et al. 2000). 
This toxicity can be due to the disorganization of the cytoskeleton caused by the tubulin 
agents, which will result in disturbances of cellular organization, intracellular transport 
and signal transduction (Baranello, Bertozzi et al. 2010). 
 
 
4.5 IDENTIFICATION OF THASPINE AS A NOVEL DUAL 
TOPOISOMERASE INHIBITOR EFFECTIVE ON SPHEROIDS 
 
Topoisomerase inhibitors are important agents in cancer therapy. Irinotecan and 
topotecan are topoisomerase I inhibitors (Pommier 2006) while doxorubicin and 
etoposide are topoisomerase II inhibitors (Baranello, Bertozzi et al. 2010). There are no 
dual topoisomerase inhibitors being in use in the clinic. Dual topoisomerase inhibitors 
have the benefit of targeting the two enzymes which are activated at different cell cycle 
time points. Additionally, they have the advantage of overcoming topoisomerase-
dependent drug resistance which might occur in either of the enzymes. Using 
combination of specific inhibitors of topoisomerase I & II gave encouraging preclinical 
results, however clinical trials suffered from additive toxicities. Accordingly, single 
dual topoisomerase compounds might represent promising agents for cancer treatment 
(Stewart, Mistry et al. 2001).   
 
Resistance is the major factor for cancer treatment failure. There are different forms of 
resistance found in solid tumors either in the cellular or the multicellular levels. One 
important mechanism of resistance to clinically used DNA damaging anticancer drugs 
is the expression of ABC transporters such as Pgp and MRP (Ling 1997). It is therefore 
interesting that thaspine cytotoxicity was marginally affected by such transporters. In 
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addition to being a top hit in the monolayer screen, we found that thaspine induced 
widespread apoptosis in HCT116 multicellular spheroids. 
 
Thaspine induced apoptosis in vivo, and induced a short period of growth retardation of 
xenograft tumors in vivo. It is possible that thaspine can be developed into an effective 
drug for clinical use. Formulation work is required since the compound is lipophilic 
with XlogP value of 2.8. It is possible that a better formulation of the compound will 
generate more sustained growth retardations of tumors compared to those observed to 
date. Thaspine should perhaps also be combined with a cytostatic agent to inhibit tumor 
growth between treatment cycles as discussed above. 
 
 
4.6 IDENTIFICATION OF CB21 AS A NOVEL IRON CHELATOR 
EFFECTIVE ON SPHEROIDS  
 
CB21 showed an interesting profile of activity by being cytotoxic to HCT116 spheroids 
but not to non-proliferating immortalized hTERT-RPE1 cells. Our experiments showed 
that the compound works through depleting intracellular iron. Iron is essential for cell 
proliferation and viability (Le and Richardson 2002). Its presence in ribonucleotide 
reductase is vital for the enzyme activity and therefore necessary for DNA synthesis 
(Nordlund and Reichard 2006)This is evidenced by the occurrence of G1-S arrest on 
iron depletion (Yu, Wong et al. 2006). Accordingly, cancer cells have a higher demand 
for iron because of their high proliferation rate compared to their normal counterparts 
(Yu, Wong et al. 2006). This fact can be exploited to use iron chelators as effective 
anticancer agents with acceptable therapeutic window. 
 
Iron plays an important role in cellular energy production (Sariban-Sohraby, Magrath et 
al. 1983) and is required as a cofactor for oxygen-binding proteins (Le and Richardson 
2002). About 50% of cellular ATP in cancer cells is produced by oxidative 
phosphorylation (Sariban-Sohraby, Magrath et al. 1983) . The iron chelator 
deferoxamine was found to inhibit the citric acid cycle enzymes aconitase, citrate 
synthase, isocitric dehydrogenase, and succinate dehydrogenase (Oexle, Gnaiger et al. 
1999). Consequently, exposure to deferoxamine resulted in reduced oxygen 
consumption, decreased ATP production and increased glycolysis and thus increased 
glucose utilization (Oexle, Gnaiger et al. 1999). We found that CB21 reducted oxygen 
consumption both by direct measurements and by staining sectioned treated spheroids 
by pimonidazole as a hypoxia marker. One possible explanation for reduced oxygen 
consumption is the inhibition of mTOR observed after CB21 treatment. It has been 
shown that the iron chelator deferasirox inhibits mTOR signaling through the induction 
of the hypoxia induced gene REDD1 (also referred to RTP801) and its down-stream 
protein, tuberin (TSC2) (Ohyashiki, Kobayashi et al. 2009). The mTOR pathway is 
known to regulate the mitochondraial oxygen consumption (Schieke, Phillips et al. 
2006) . However, the PI3K/mTOR inhibitor NVP-BEZ235 did not show cytotoxicity in 
the spheroids core cells, meaning that mTOR inhibition is not the only mechanism for 
CB21 cytotoxicity. Interestingly, CB21 lead to increased dependence on glucose 
revealed by slight increase in glucose uptake and enhanced drug-toxicity in glucose free 
medium. We observed death of core cells in spheroids when grown in glucose depleted 
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medium indicating the dependence of this subpopulation on glucose. Possibly, 
available glucose,  in the core cells, which are already subjected to lower concentration 
than outer cells, is not enough to keep cells viable after the oxidative phosphorylation 
inhibition caused by CB21. 
 
The ability of the iron chelator CB21 to inhibit cell proliferation was expected and can 
be explained by ribonucleotide reductase inhibition. In contrast, the toxicity to the non-
proliferating cells subpopulation in spheriods was unexpected.  CB21 induced 
pronounced autophagy both in HCT116 monolayers and spheroids. In contrast, 
autophagy was not as pronounced in immortalized hTERT-RPE1 cells. Autophagy is a 
self digestion process mediated by HIF-1 (Jiang, Semenza et al. 1996). During normal 
conditions, autophagy functions as a process by which damaged proteins and organelles 
accumulate in autophagosomes which fuse with endo/lysosomes for degradation 
(White, Karp et al. 2010). However, during conditions of nutrient limitation, autophagy 
is induced to catabolize degraded constituents for ATP production (Brahimi-Horn, 
Bellot et al. 2011). We did not observe decreases in cellular ATP levels after treatment 
with CB21, and it is possible that ATP production might have been compensated by 
autophagy. Then, we can understand that autophagy induction is a mechanism by 
which cells try to rescue themselves from an energy problem caused by CB21.  It is 
worthwhile here to note that the mTOR inhibitors NVP-BEZ235 and rapamycin did not 
induce autophagy to a similar extent as CB21, indicating that mTOR inhibition is not 
the main mechanism by which CB21 toxicity occurs. 
 
Inhibiting autophagy by treatment with 3-MA (3-methyl adenine), Bafilomycin A or by 
silencing Beclin/Atg6 caused increased toxicity by CB21. This observation is 
consistent with the hypothesis that autophagy is a rescue mechanism in CB21-treated 
cells. Recent studies showed that autophagy inhibitors potentiated the cytotoxic effect 
of anticancer agents (Livesey, Tang et al. 2009). For example, chloroquine, the 
antimalarial agent, which is an autophagy inhibitor as well, increased the cytotoxic 
effect of 5-FU in HT29 cell line (Sasaki, Tsuno et al. 2010). Another example, 
chloroquine, 3-MA and siRNA targeting Atg7 enhanced cell killing of Src family 
kinase (SFK) inhibitors (Wu, Chang et al. 2010). The strong induction of autophagy in 
response of CB21 raises the possibility that autophagy inhibition in combination with 
the iron chelator could be a powerful treatment for solid tumors. One may speculate 
that autophagy may be particularly important for the viability of cells in the hypoxic 
core of tumors, and that these cells are very sensitive to CB21 in the presence of 
autophagy inhibitors. 
 
The main aim for using spheroids for drug screening is that such screen identifies 
compounds with high probability to be active in vivo. Indeed, CB21 showed promising 
activity when tested on a mice xenograft model bearing HCT116 tumors, the same cell 
line in which the original screen was performed.  
 
Iron chelators are expected to induce very complex effects on cells. We observed both 
an induction of p53 and of HIF-1. HIF-1 is known to be a central mediator for cell 
adaptation to hypoxia conditions (Jiang, Rue et al. 1996). In presence of oxygen, the 
regulatory subunits of HIF including  HIF-1α are hydroxylated in two prolines by 
prolyl-hydroxylases (PHDs) leading to degradation of HIF through ubiquitination and 
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proteasomal degradation (Semenza 2007; Peyssonnaux, Nizet et al. 2008). In hypoxic 
conditions PHDs are inhibited leading to stabilization of the non-hydroxylated active 
form of HIF. Not only hypoxia causes inactivation of PHD but also iron depletion 
(Peyssonnaux, Nizet et al. 2008). This explains the upregulation of  HIF-1α on 
treatment with CB21 inspite of the increase in normoxic area in sections of CB21 
treated spheroids stained with the hypoxia marker pimonidazole. We do not at present 
understand the respective roles of the various responses to CB21, but believe that the 
main effects are inhibition of ribonucleotide reductase, induction of autophagy (due to 
an underlying metabolic alteration), and inhibition of oxygen consumption possibly due 
to mTOR inhibition.   
 
CB21 was found to be more potent in cytotoxicity assays compared to other iron 
chelators, including deferoxamine. Though deferoxamine showed some antitumor 
activity in leukemia and neuroblastoma, its efficacy is limited by its poor membrane 
penetration. Triapine is considered one of the most studied iron chelators for antitumor 
activity and already entered clinical trials (Richardson 2002). Though showed some 
activity, it was not sufficiently effective and was limited by toxic side effects at a dose 
of 160 mg/m2/d (Yu, Wong et al. 2006). Whether CB21, alone or in combination with 
autophagy inhibitors, will be more effective is not known but it would be quite 
interesting to perform clinical trials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (6). (A). Regulation of HIFA by oxygen and iron. (B). Proposed cellular effects of the iron chelator CB21. 
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4.7 SUMMARY 
 
Several factors contribute for an efficient chemotherapeutic agent for treatment of solid 
tumors. Both pharmacokinetic and pharmacodynamic properties are determinant 
elements for a successful anticancer agent. We should also take in consideration the 
severe side effects of chemotherapy which limit the dosage and continuation of 
treatment. The new targeted anticancer agents provide a hope for a milder 
chemotherapy. However, the heterogeneous genomic nature of cancers, within the same 
tumor or between different tumors, provides and significant challenge for such agents. 
Accordingly, we believe that cytotoxic agents hitting vital targets in cancer cells would 
provide more efficiency in treatment of cancer, nevertheless, it is expected to be toxic 
to normal cells as well.  
 
In the present study, we tried to optimize a cell based approach to identify cytotoxic 
agents against tumor masses grown as spheroids. This model allows the selection of 
penetrating cytotoxic agents against proliferating and hypoxic non-proliferating 
resistant cancer cells. In other words, compounds possessing favorable pharmacokinetic 
and pharmacodynamic characteristics. In order to exclude the identification of 
compounds toxic to normal cells, we set up spheroids from a normal human cell line as 
a counter screen. This system resulted in the identification of an iron chelator and 
antitubulin agents. The iron chelator indeed showed promising in vivo activity and was 
tolerated by mice. 
 
Another important finding was the enrichment of the spheroid screen for lipophilic 
compounds. Thus, the physicochemical properties of an anticancer agent should be 
taken into consideration in drug design and not to be overlooked. 
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